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This thesis is a “Thesis incorporating publications”. This implies that certain sections or 
chapters will be taken from published journal articles which I am the first author of. 
For instance, sections in the introduction are taken from my review article which has 
been published in Current Pharmaceutical Design (Englund et al., 2012), and the 
chapter “The cognitive and psychological effects of ∆9-THC and CBD” is an original 
article published in Journal of Psychopharmacology (Englund et al., 2013). As the entire 
chapter is made up of the published article, it will also be preceded and followed by 
additional comments. The various measurements used for the experiments will be 




Table of content 
Abstract        9-10 
Introduction        11-32 
Cognitive and Psychological effects of ∆9-THC and CBD  33-59 
Electrophysiological effects of ∆9-THC and CBD   60-96 
Cognitive and Psychological effects of ∆9-THC and ∆9-THCV 97-126 
Summary and Discussion      127-134 
Appendices        135-163 




Table of figures  
Box 1. Early medical use of cannabis in Asia and Africa 
Box 2. Effects of cannabis intoxication among recreational users 
Image 1 The three subspecies of the cannabis plant 
Image 2 Glandular trichomes of the cannabis plant  
Image 3 Cannabinoid biosynthesis 
Image 4 Endocannabinoid signalling 
Table 1 List of intravenous cannabinoid studies 
Table 2.1 Time course of experimental day of study 1 
Table 2.2 Sample characteristics of study 1 
Figure 2.1 Plasma cannabinoid concentration of study 1 
Figure 2.2 PANSS positive score of study 1 
Table 2.3 Frequency of clinically significant psychosis of study 1 
Figure 2.3 SSPS score of study 1 
Table 2.4 Cognitive performance of study 1 
Figure 2.4a + b Immediate and delayed verbal recall of study 1 
Table 3.1 Experimental timeline for EEG recording of study 1 
Table 3.2 Participant demographics of EEG analysis 
Table 3.3 EEG electrode grouping 
Figure 3.1 Location of EEG electrodes 
Figure 3.2 Percentage correct responses on the N-back task 
Figure 3.3 Reaction time on the N-back task 
7 
 
Figure 3.4 PANSS positive score for EEG analysis 
Figure 3.5 SSPS score for EEG analysis 
Figure 3.6. Alpha amplitude according to electrode location 
Figure 3.7. Alpha amplitude change across sessions for each scalp location 
Figure 3.8. Alpha amplitude across sessions for each group 
Figure 3.9. Beta amplitude according to electrode location 
Figure 3.10. Beta amplitude change across sessions for each scalp location 
Figure 3.11. Beta amplitude across sessions for each group 
Figure 3.12. Delta amplitude according to electrode location 
Figure 3.13. Delta amplitude change across sessions for each scalp location 
Figure 3.14. Delta amplitude across sessions for each group 
Figure 3.15. Theta amplitude according to electrode location 
Figure 3.16. Theta amplitude change across sessions for each scalp location 
Figure 3.17. Theta amplitude across sessions for each group 
Figure 3.18. Gamma amplitude according to electrode location 
Figure 3.19. Gamma amplitude change across sessions for each scalp location 
Figure 3.20. Gamma amplitude across sessions for each group 
Figure 3.21. Bi-frontal Alpha coherence across sessions 
Figure 3.22. Bi-frontal Theta coherence across sessions 
Figure 4.1 Timeline of experimental weeks of study 2 
Table 4.1. Participant demographics of study 2 
Table 4.2 Effects of ∆9-THCV and placebo 
Figure 4.2 A. Delayed verbal recall of study 2 
8 
 
Figure 4.2 B. Memory intrusions of study 2 
Figure 4.3 Reverse digit span of study 2 
Figure 4.4 A. CAPE positive symptoms of study 2 
Figure 4.4 B. CAPE negative symptoms of study 2 
Figure 4.5 A. UMACL hedonic tone of study 2 
Figure 4.5 B. UMACL energetic arousal of study 2 
Figure 4.5 C. UMACL tense arousal of study 2 
Figure 4.6 Beck’s anxiety inventory of study 2 
Figure 4.7 A. VAS “anxious” of study 2 
Figure 4.7 B. VAS “high” of study 2 
Figure 4.7 C. VAS “stoned” of study 2 
Figure 4.8 Heart rate of study 2 
Figure 4.9 A. Plasma ∆9-THC and 11-OH-∆9-THC concentration of study 2 
Figure 4.9 B. Plasma ∆9-THCV and 11-OH-∆9-THCV concentration of study 2 
Figure 4.10 A. Subjective experience of pleasure of study 2 






The cannabis available in many countries has been changing in recent years to favour a 
product increasingly high in its main component, the cannabinoid ∆9-THC. 
Epidemiological studies have highlighted that early, persistent and heavy cannabis use, 
particularly for cannabis high in ∆9-THC, is associated with an increased risk of 
development of schizophrenia. However, cannabis is a complex plant which also 
produces over 100 other cannabis compounds, each with a unique pharmacological 
profile. Cannabinoids such as CBD and ∆9-THCV, which are virtually absent from 
cannabis sold on the black market in the UK today, may interfere pharmacologically 
with ∆9-THC and therefore protect against the negative effects associated with 
cannabis use. 
This thesis is comprised of two experimental studies in healthy volunteers where the 
cognitive, psychological and electrophysiological effects of ∆9-THC, CBD and ∆9-THCV 
are explored.  
Study 1 
In the first part of study 1, the psychological and cognitive effects of ∆9-THC and CBD 
were explored in a placebo-controlled, between-subjects design with 48 healthy 
volunteers. Pre-treatment with CBD (600mg, oral) significantly inhibited IV ∆9-THC-
induced (1.5mg) paranoia and impairments to delayed verbal recall. Also, significantly 
fewer participants experienced clinically significant psychotic symptoms following IV 
∆9-THC if pre-treated with CBD compared to placebo. 
In the second part of study 1, the electrophysiological effects of ∆9-THC and CBD were 
explored in the same sample, although the data from three participants were 
excluded. I found that ∆9-THC significantly reduced theta amplitude and coherence, 
although these were not correlated with psychopathology or inhibited by CBD. 
However, ∆9-THC-induced increases of alpha and delta amplitude was significantly 






The second study was a within-subject, placebo-controlled, cross-over design study 
(N=10), exploring the effects of IV ∆9-THC (1mg) and ∆9-THCV (10mg/day oral for 5 
days) in healthy male volunteers with minimal past cannabis  use. I found that ∆9-THC 
did not produce significant increases in paranoia or psychosis, or impairments to 
immediate verbal recall. ∆9-THCV significantly inhibited ∆9-THC-induced heart-rate 
increase and impairments to delayed verbal recall. ∆9-THCV on its own produced a 
significant improvement in reverse digit span, and a trend towards increased anxiety. 
 Together, these results highlight the important protective role that CBD and ∆9-THCV 
play in recreational cannabis use against the negative effects of ∆9-THC. It also raises 
the possibility that CBD and ∆9-THCV may hold therapeutic value for mental illness and 






“Weary with toil, I haste me to my bed, 
The dear repose for limbs with travel tired; 
But then begins a journey in my head, 
To work my mind, when body’s work’s expired…..” 
- William Shakespeare, Sonnet 27 
 
It has been argued that Shakespeare is referring to the use of cannabis in this sonnet, 
as well as in sonnet 76 where he makes references to “compounds strange” and 
“noted weed”. This has been hypothesised as a study found traces of cannabis and 
cocaine in pipes dug up from his home in Stratford-upon-Avon (Thackeray et al., 2001). 
Although this claim has been criticised, the use of cannabis has been pervasive in 
recent and ancient history for its mind-altering, therapeutic and spiritual effects 
(Touw, 1981). The first archaeological evidence of cannabis used by humans was found 
in China roughly 6000 years ago (Li, 1973), which indicated its cultivation for use of 
fibres rather as a psychoactive substance. The early medicinal use of cannabis has 
been extensively documented throughout Asia and Africa (Zuardi, 2006) (See Box.1), 
including Egypt (Russo, 2007).  
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Nowadays recreational cannabis use is widespread across the world with an estimated 
125-203 million people between the ages of 15-64 having used it at least once in the 
last year (UNDOC, 2011). It is estimated that roughly 9% of people who experiment 
with cannabis go on to develop dependence (Hall and Degenhardt, 2014). The rates of 
dependence among daily users range between 25-50% (Coffey et al., 2003). 
Cannabis is most commonly used by smoking the dried flowering tops of the cannabis 
plant, often together with tobacco in a rolled cigarette (aka. joint). However, cannabis 
may also be eaten by incorporating it into cooked or baked food items (usually in fat, 
as the active components are fat soluble). The effects of smoked cannabis come on 
after a few minutes and last for roughly 2-3 hours, while eaten cannabis can take up to 
2 hours before the effects are felt and can last for up to 8 hours (Jones and Stone, 
1970). Presently and historically, cannabis is used medicinally to relieve certain 
symptoms and for various spiritual purposes, although it is most commonly used 
recreationally for its pleasurable effects. Cannabis produces a myriad of effects on the 
user which will vary not only between people, but also between moods and settings. 





The cannabis plant is thought to originate from either Central Asian or the foothills of 
the Himalayan Mountains (Clarke and Watson, 2007) and is considered by some to be 
subdivided into 3 species: Cannabis Sativa, Cannabis Indica (aka. Afghanica), and 
Cannabis ruderalis (Hillig and Mahlberg, 2004). However, this is merely based on 
typology and morphology of the plants (see Image 1) rather than differences in the 
plants genetics or chemical composition, as most taxonomists consider cannabis to be 
monotypic (Harlan and de Wet, 1971; Small and Cronquist, 1976). The chemical 
compounds specific to the cannabis plant are known as cannabinoids, and the most 
common among them include ∆9-tetrahydrocannabinol (∆9-THC), ∆9-
tetrahydrocannabivarin (∆9-THCV), cannabidiol (CBD), cannabinol (CBN), cannabigerol 
(CBG), cannabichromene (CBC) amongst others. It is estimated that cannabis contains 
over 108 different cannabinoids, along with roughly 400 other compounds such as 




Image 1. The three typological divisions of the cannabis plant, adapted from 
(Wikipedia, n.d.) 
  
These chemical compounds are produced in glandular trichomes, mostly around the 
flowering tops of the plant and, to a far lesser extent, the leaves (Clarke and Watson, 
2007) (see Image 2). Within the heads of these resin glands, the cannabinoids are 
stored within vesicles and protected from oxidative and enzymatic degradation by the 
glands waxy outer layer. The trichomes are thought to protect the plant against cold 
winds (Mahlberg et al., 1984), reflecting both infrared and ultraviolet rays (hence 
cooling the plant and reducing sunburn) (Roberecht et al., 1980), and protecting 
against UV radiation (Rhoades, 1977). Furthermore, bitter sesquiterpenes in the 
trichomes are thought to repel herbivores and their sticky and glutinous composition 
trap insects which prevent them from feeding and colonizing of the plant (Potter, 
2009). The cannabinoids make up more than 80% of the trichomes and can sometimes 
make up 30% of the total weight of the flowering tops when dried (Russo, 2007; Clarke 
and Watson, 2007). ∆9-THC, CBD and CBC are produced from the same precursor CBG, 
each by means of a separate enzymes (Taura et al., 1995, 1996). The ratios of these 
enzymes also determine the ratio of cannabinoids the plant produces, and is 
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determined by a single allele: T, D and C (see Image 3). T and D alleles are co-dominant 
and depending on the genetic makeup of the plant, it will produce either a ∆9-THC 
dominant plant, a CBD dominant plant, or a plant with roughly equal levels of ∆9-THC 
and CBD.  





Image 3. Cannabinoid biosynthesis, adapted from (Clarke and Watson, 2007) 
 
 
Another important factor determining the potency of the plant is whether or not the 
female plant is pollinated and starts the production of cannabis seeds. Once pollinated, 
the female plant devotes vast amounts of energy into seed production, while 
unpollinated plants keep producing cannabinoids in great quantities (Potter, 2013). 
These unpollinated female plants are commonly referred to as sinsemilla, which is 
Spanish for “without seed”. Today, it is this type of T allele dominant sinsemilla 
cannabis, strains which are high in ∆9-THC and almost devoid of CBD, which dominates 
the UK black market (Potter et al., 2008). Cannabis resin (also known as hash) which is 
extracted from the cannabis plant, is usually very high in trichomes which also 
contributes to its high potency (Pijlman et al., 2005). In the UK however, hash is 
imported from North Africa where cannabis-farmers select plants which produce the 
greatest yield rather than potency, resulting in a plant which has roughly equal levels 
of ∆9-THC and CBD (Potter et al., 2008; Clarke and Watson, 2007). Furthermore, the 
plants are allowed to become fertilised which also contributes to a lower potency. 
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Currently in the UK, cannabis is mainly grown indoors under intense lighting conditions 
(Hardwick and King, 2008). Although this has not been found to affect ∆9-THC potency 
of the product, it does increase the proportion of floral material resulting in a greater 
yield (Potter and Duncombe, 2012). As a more potent cannabis product is likely to 
incur greater profits for the producers, this may explain why there has been a push in 
the recent decade towards more potent cannabis varieties grown under intense indoor 
lighting conditions (King et al., 2004; Potter et al., 2008; Hardwick and King, 2008). 
The Endocannabinoid system  
The cannabinoids exert their effect on the mind by interacting with the endogenous 
cannabinoid system (ECS) (Devane et al., 1988) as well as many other pharmacological 
targets. The endocannabinoid system refers to a set of endogenous ligands, their 
receptors, and the enzymes that synthesize and degrade them. Twenty years after the 
discovery of the structure of ∆9-THC (Gaoni et al., 1964) researchers identified a 
cannabinoid-specific receptor: cannabinoid receptor type-1 (CB1) (Devane et al., 1988), 
shortly followed by cannabinoid receptor type-2 (CB2) (Munro et al., 1993). The 
cannabinoid receptors belong to the super-family of G-protein coupled receptors with 
densities about 10-50 times that of classical neurotransmitters such as opioid or 
dopamine receptors (Howlett et al., 1990). The CB1 receptor is predominantly found in 
the central nervous system with the highest concentrations in the neocortex, basal 
ganglia, hippocampus, cerebellum, and anterior olfactory nucleus (Glass et al., 1997). 
Moderate concentrations of CB1 are also present in the hypothalamus, basolateral 
amygdala, and the periaqueductal gray matter in the midbrain. The CB2 receptor was 
initially thought to be localized only in immune cells in the periphery (Piomelli, 2003), 
but has more recently also been found in the cerebellum and brain stem (Suárez et al., 
2008). 
To date, several endogenous cannabinoid receptor ligands have been found; the most 
well-known are N-arachidonoylethanolamide (Anandamide, AEA) (Devane et al., 1992) 
and 2-arachidonoylglycerol (2-AG) (Mechoulam et al., 1995). These are biosynthesized 
post-synaptically in an activity-dependant manner (Fernandez-Espejo et al., 2009). CB1 
receptors are predominantly pre-synaptic, occurring on the terminals of GABAergic 
and glutamatergic neurons. The relative dominance of CB1 receptors on GABAergic 
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neurons vs glutamatergic ones differ depending on brain region. For instance, in the 
hippocampus, CB1 receptors are found at higher densities on GABAergic neurons 
compared to glutamatergic (Monory et al., 2006). Activation of CB1 receptors leads to 
a decrease of pre-synaptic neurotransmitter release. Endocannabinoids regulate 
GABAergic and glutamatergic over short and long-term durations by adjusting synaptic 
weight (synaptic plasticity) (Fernandez-Espejo et al., 2009). Clearance of AEA and 2-AG 
is by a re-uptake mechanism and enzymatic hydrolysis, fatty acid amide hydrolase 
(FAAH) for AEA and monoacylglyceride lipase (MAGL) for 2-AG (Dinh et al., 2002) (see 
Image 4). 
 





Endocannabinoid transmission is finely tuned, with precise mechanisms for local 
synthesis and degradation. Administration of exogenous CB1 agonists is unlikely to 
capture the subtleties of endocannabinoid signalling. Rather, disruption of endogenous 
cannabinoid dependent processes is more likely to occur. Also prolonged activation of 
the CB1 receptor by ∆9-THC can lead to desensitisation and down-regulation of the 
CB1 receptor (Hirvonen et al., 2012). 
Cannabis and cognition 
A major concern of cannabis use is its impact on cognitive functioning and learning, 
especially among younger users. This has biological plausibility as there are high to 
moderate densities of CB1 receptors in key areas of cognition, such as the 
hippocampus and frontal cortex (Glass et al., 1997). Many studies have compared long-
term heavy cannabis users to non-using healthy controls on various domains of 
cognitive performance. However, studies have varied greatly in their participant 
selection criteria and type of task employed (Schoeler and Bhattacharyya, 2013). In a 
recent longitudinal study, 1,037 participants were followed up from birth up until 38 
years of age and were administered standardised neurocognitive test batteries at 
regular intervals throughout the study. The authors reported a significant decline in IQ-
scores of 6-points among cannabis using participants who had been diagnosed with 
cannabis use disorder (CUD) at 3 testing-points or more, after the age of 18. This 
performance drop was observed even after 1 year of abstinence, although it was only 
present for users who had started using cannabis before the age of 18 (Meier et al., 
2012). This distinction of effect between different ages of onset highlight the increased 
risk related to an earlier onset of use on outcome. A recent study which collated data 
from 3 studies supports this notion as it found adolescent use to be related to poorer 
educational attainment, psychological functioning and greater likelihood of cannabis 
dependence (Silins et al., 2014). However, studies such as these are difficult to 
interpret due to the possibility of confounding variables such as mood disorders, past 
history of other drug use and academic achievement, as these factors are known to 
influence the effect sizes (Schoeler and Bhattacharyya, 2013). In fact, a yet to be 
published longitudinal study in 2,235 adolescents found that the heaviest users 
showed a 3-point drop in IQ between the ages of 8 and 15 years. However, when 
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factors such as alcohol, tobacco, other drugs, gender, socioeconomic status, maternal 
factors and mental health were included in the model, the association between 
cannabis use and IQ became non-significant (Mokrysz et al., 2014). 
Mental health as a confounder was recently studied in a comparison between 
adolescents with CUD after abstinence, controls with psychiatric disorders, and healthy 
adolescents. The authors found no difference in academic achievement between 
adolescents with psychiatric disorders, regardless of cannabis use. Furthermore, they 
noted that abstinent adolescents did not significantly differ compared to the other 
groups (Hooper et al., 2014). Seemingly, heavy cannabis users regain their cognitive 
abilities following extended periods of abstinence, which suggests that the detriments 
may be explained by withdrawal symptoms or recovering from the last use occasion. 
(Pope et al., 2001; Fried et al., 2005; Hanson et al., 2010; Tait et al., 2011). This has also 
recently been confirmed in a meta-analysis where it was concluded that 
neurocognitive impairments do not persist following 25 days of abstinence (Schreiner 
and Dunn, 2012). This field of study is further confounded by the fact that studies to 
date have been unable to control for cannabis type, where some may contain higher or 
lower levels of ∆9-THC or a presence or absence of CBD. 
Studies of the acute effects of cannabis and ∆9-THC on cognitive performance started 
in the early 1970s, when converging lines of evidence highlighted impairments to 
performance in a dose response manner (Tinklenberg et al., 1970; Miller and Cornett, 
1978). ∆9-THC impacts most areas of cognition negatively when given in high enough 
doses, although poorer performance is less marked in certain areas of executive 
functioning (Pope et al., 1995) such as verbal fluency (Morrison et al., 2009) and risk-
taking (Ramaekers et al., 2006a). The domains of cognition which are most robustly 
impacted by ∆9-THC are those of immediate and delayed recall (verbal and digit) 
(Ranganathan and D’Souza, 2006; Schoeler and Bhattacharyya, 2013), whereas 
learning (D’Souza et al., 2004; Morrison et al., 2009; D’Souza, Braley, et al., 2008) and 
recognition recall are not affected (D’Souza et al., 2004; D’Souza, Ranganathan, et al., 
2008; Liem-Moolenaar et al., 2010; Kleinloog et al., 2012). Also, heavy users are not as 
negatively affected by cannabis as occasional users (Ramaekers et al., 2009; Hart et al., 
2001, 2002). This was highlighted in a study administering large intravenous doses to 
frequent and occasional users (D’Souza, Ranganathan, et al., 2008), which showed 
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heavy users performing worse on both immediate and delayed recall compared to 
occasional users. However, for each subsequent increased dose of ∆9-THC, the 
frequent users outperformed the controls and the memory impairment was 
significantly less pronounced in the frequent users. The poor baseline performance 
which the heavy users showed might be due to withdrawal experienced during the 
drug-free baseline condition. This would then account for the stable or improved 
performance among frequent users following THC administration, while occasional 
users would display impairment.  
A few studies have explored the potential inhibitory effects of the commonly 
prescribed antipsychotic medications Haloperidol and Olanzapine on ∆9-THC effects in 
healthy volunteers. These studies have found that both antipsychotics and ∆9-THC 
impair immediate and delayed recall on their own to a comparable degree (D’Souza, 
Braley, et al., 2008; Kleinloog et al., 2012; Liem-Moolenaar et al., 2010). However, 
when administered together, antipsychotics further exacerbate the cognitively 
impairing effects of ∆9-THC.  These results suggest that the cognitively impairing 
effects of cannabis and ∆9-THC does not relate directly to the dopaminergic system, 
which these drugs target. 
Cannabidiol has been shown in animal models of cognitive impairment to improve 
cognition (Barichello et al., 2012; Avraham et al., 2011; Magen et al., 2010; Fagherazzi 
et al., 2012), as well as protecting against the memory impairing effects of ∆9-THC 
(Fadda et al., 2004). In a naturalistic study, Morgan and colleagues took samples of test 
subjects’ own cannabis to analyse for cannabinoid content and had them perform 
cognitive tasks once while drug free and once while intoxicated. They found that 
participants who smoked cannabis higher in CBD did not show any impairments in 
immediate or delayed recall during intoxication, while the participants who smoked 
cannabis with only ∆9-THC were significantly impaired (Morgan, Schafer, et al., 2010). 
The same group later studied daily and recreational cannabis users and collected hair 
samples which were analysed for ∆9-THC and CBD content. When comparing the two 
groups, the authors found a significant improvement in recognition memory in the 
group that had CBD present in hair samples (Morgan et al., 2012). Taken together, 
these studies highlight the cognitively protective properties of CBD against ∆9-THC 
induced impairments. They also suggest that manipulation of the endocannabinoid 
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system (using other cannabinoids such as CBD or ∆9-THCV) may serve as a better 
target against the memory impairing effects of cannabis rather than the dopaminergic 
system. However, no study to date has studied the protective effects of CBD on ∆9-
THC in humans using carefully controlled doses of the two compounds.  
Cannabis and psychosis 
“...ma-fen (fruit of the cannabis plant), if taken in excess will produce visions of 
devils ... over a long term, it makes one communicate with spirits and lightens 
one’s body...” 
 - Pen-ts’ao ching, Chinese pharmacopeia 2700 BC 
Although there had been many suspicions of a link between cannabis use and 
psychotic illness, the first real evidence came from a large cohort study from Sweden 
in 1987. The study followed roughly 50,000 military conscripts for 15 years and showed 
that people who had reported cannabis use at conscription had an increased likelihood 
of being diagnosed with schizophrenia at follow-up (Andréasson et al., 1987). 
Furthermore, they found that the heaviest users had a 6-fold increased risk compared 
to non-users. Although this study received much attention, it was not until the early 
and mid 2000s that further research began to emerge. These studies lend further 
support to the association between the use of cannabis and psychotic illness, with an 
earlier onset and more frequent use being related to higher risk (Arseneault et al., 
2002; Fergusson et al., 2005; van Os, 2002). In 2007, a meta-analysis put together the 
results of the best studies to date and found that having ever used cannabis increased 
the risk of psychotic outcome by 40%, and for daily users the risk was doubled (Moore 
et al., 2007). However, a few newer studies have highlighted nuances to this 
relationship. A recent case-control study found that the use of stronger cannabis 
incurred an even greater risk of psychosis while use of weaker cannabis was not 
related to an increased risk (Di Forti et al., 2015). Furthermore, a gene which is 
involved in the dopaminergic signalling cascade in the striatum by coding for a certain 
protein kinase, AKT1, has surfaced as a potential mediating factor between cannabis 
and psychosis. A recent case-control study found that only carriers of the C/C variant 
of the AKT1 gene had an elevated risk of psychosis when they used cannabis every day 
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(Di Forti et al., 2012). AKT1 has also been found to modulate the cognitive effects of 
cannabis in a population of psychotic patients (van Winkel et al., 2011). Another gene 
which holds theoretical plausibility is the gene which codes for the CB1 receptor, 
CNR1.  Studies to date have yielded mixed findings with regards to variations of the 
CNR1 gene and psychosis (Chavarría-Siles et al., 2008; Martínez-Gras et al., 2006; Leroy 
et al., 2001; Seifert et al., 2007; Tsai et al., 2000; Zammit et al., 2007; Ujike et al., 
2002). The largest of these studies failed to find an association between the CNR1 gene 
and psychosis, nor an interaction between the CNR1 gene and cannabis use (Zammit et 
al., 2007). 
The issue of whether cannabis is causality related to psychotic illness has still not been 
adequately addressed. A longitudinal study showed that although cannabis use at age 
16 predicted psychosis at age 19, psychotic symptoms at age 13 and 16 predicted 
cannabis use at age 16 and 19 respectively (Griffith-Lendering et al., 2013). Studies 
such as this and others like it (Cassidy et al., 2011; Ferdinand et al., 2005) suggest that 
the relationship might be bi-directional, highlighting the alternative explanation of 
psychotic symptoms or vulnerability might make cannabis use more likely, and vice 
versa. Furthermore, there may be other mediating factors which both increase risk for 
psychosis as well as increase likelihood of heavy cannabis use. For instance, familial 
risk (having relatives with psychotic illness) has been found to explain the risk between 
cannabis use and psychotic illness (Proal et al., 2014), although this may be explained 
as cannabis triggering an underlying vulnerability (McGuire et al., 1995). Twin studies 
have also highlighted that heavy cannabis use has a strong genetic component 
(Kendler and Prescott, 1998; Kendler et al., 2002). Although environmental factors play 
a clear role in whether or not someone tries cannabis, the heritability of heavy 
cannabis use, abuse and dependence is significantly higher and ranges between 45-
78% across studies (Lynskey et al., 2002; van den Bree et al., 1998; Rhee et al., 2003; 
Kendler and Prescott, 1998; Kendler et al., 2000). Examining the literature more closely 
it becomes evident that there is greater heritability for heavy cannabis use compared 
to dependence (79% vs 62% (Kendler and Prescott, 1998), 84% vs 58% (Kendler et al., 
2000),64% vs 45% (Lynskey et al., 2002)), which suggests that environmental factors 
play a greater role in the occurrence of dependence. Furthermore, there is a significant 
coherence between subjective effects where roughly a quarter of the variance for both 
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negative and positive cannabis effects were determined by genetic factors (Lyons et 
al., 1997). 
A significant confound for the association between cannabis use and psychosis is use 
of tobacco, as cannabis is commonly smoked together with tobacco. Tobacco use is 
highly prevalent among patients with psychosis and a meta-analysis found a strong 
association between psychosis and tobacco use (Myles, H. D. Newall, et al., 2012), 
although a separate meta-analysis found no association with age at onset of psychosis 
(Myles, H. Newall, et al., 2012). However, a recent study found that age at first tobacco 
use was related to several measures of psychotic like experiences and still related to 
hallucinations when all participants with any cannabis experience were excluded 
(McGrath et al., 2015). In a cross-sectional survey study, use of tobacco and cannabis 
were equally strongly associated with psychotic like experiences, although the 
association between cannabis and psychotic like experiences became non-significant 
when controlling for tobacco (van Gastel et al., 2013). Similar results were found in a 
longitudinal study of adolescents, where both use of cannabis and tobacco at age 16 
were equally related to psychotic like experiences at age 18 (Gage et al., 2014). 
Additional longitudinal studies with more precise measures of cannabis and tobacco 
exposures are needed to disentangle these associations. 
From the studies presented above it is clear that the association between cannabis use 
and psychosis is highly complex and far from straight forward. However, it is widely 
accepted today that cannabis use is a component cause, which implies that it is not a 
necessary or sufficient cause of psychotic illness, but potentially a mediating or 
catalytic factor (van Winkel and Kuepper, 2014; Murray et al., 2007). 
The acute psychotic-like effects of cannabis are far less controversial or contentious. In 
as early as the mid-1800s, the French psychiatrist Jacques-Joseph Moreau extensively 
reported the effects of eating large quantities of hash and encouraged his students to 
do the same (Moreau J, 1845). He considered psychoactive substances to be both the 
cure and cause of mental illness, and famously said: “I saw in hashish, more specifically 
in its effects on mental abilities, a powerful and unique method to investigate the 
genesis of mental illness”. Although the psychotogenic effects of cannabis had been 
reported in the literature between the 1950s to 1980s in studies and observations 
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(Ames, 1958; Talbott, 1969; Chopra, 1974; Isbell et al., 1967; Melges, 1976), these 
reports did not make use of standardised clinical scales to assess the severity and 
intensity of these symptoms. It would take until 2004 when D’Souza and colleagues 
studied the effects of ∆9-THC in 22 healthy volunteers using the Positive and Negative 
Syndrome Scale (PANSS). They showed that ∆9-THC, in a dose dependent manner 
increased positive, negative and general psychotic symptoms (D’Souza et al., 2004) as 
measured by the PANSS. They later went on to show that ∆9-THC would also induce 
psychotic symptoms or exacerbate pre-existing symptoms in patients with 
schizophrenia who were symptomatically stable on medication (D’Souza et al., 2005). 
These findings were later replicated by Morrison and colleagues where ∆9-THC 
induced psychotic symptoms on not only the PANSS, but also a self-rated scale known 
as the Community Assessment of Psychic Experiences (CAPE) (Morrison et al., 2009). 
Interestingly, although these studied administered doses considered much higher than 
what most recreational users would take (Englund et al., 2012), only 40-50% of healthy 
participants experienced psychotic symptoms, and inter-individual variation was high 
(Morrison et al., 2009; D’Souza et al., 2004). 
A compound which is capable of inducing psychotic symptoms in a subset of healthy 
individuals lends itself as being a tool to study the mechanics and possible treatment 
of psychosis. This has been particularly true for amphetamine or cocaine induced 
psychosis, where dopamine blocking drugs such as haloperidol are effective at 
alleviating psychotic  symptoms (Awouters and Lewi, 2007). In line with this thought of 
reasoning, drugs which block the psychotogenic effects of ∆9-THC may also be 
effective in treating psychotic illnesses such as schizophrenia. Similarly, drugs which 
are effective at treating symptoms of psychosis may also be effective at reducing the 
psychotogenic effects of cannabis. A few studies to date have explored the effects of 
co-administering anti-psychotic drugs with ∆9-THC to healthy volunteers. The study 
with the most reliable administration route, intravenous (IV) injection of ∆9-THC, 
showed that pre-treatment with haloperidol did not significantly reduce the 
psychotogenic effects of ∆9-THC and further worsened the cognitive effects of the 
injection (D’Souza, Braley, et al., 2008). Two studies have looked at the effects of 
haloperidol and olanzapine on inhaled ∆9-THC in healthy volunteers and found 
significant yet weak reductions in psychotic symptoms (Kleinloog et al., 2012; Liem-
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Moolenaar et al., 2010). These findings are in line with most studies in healthy 
volunteers showing no significant increase of dopamine in the striatum following 
administration of ∆9-THC (Barkus et al., 2011; Stokes et al., 2009; Bloomfield et al., 
2013; Bossong et al., 2009). However, a recent study did show that dopamine was 
significantly increased by ∆9-THC, but only among patients with schizophrenia and 
their relatives (Kuepper et al., 2013). A recent study which combined data from two 
separate PET studies found that ∆9-THC did significantly increase striatal dopamine 
levels in healthy volunteers, although not to a level which would be expected in 
psychosis (Bossong et al., 2015). Furthermore, a PET study in healthy volunteers did 
find significant dopamine release following THC in the right middle frontal gyrus, left 
superior frontal gyrus and left superior temporal gyrus; although none of these 
increases were related to psychotic symptoms (Stokes et al., 2010). Seemingly, it 
appears that the dopamine system might be less involved with ∆9-THC induced 
psychotic symptoms, apart from those who have a family history of psychotic illness. 
Cannabidiol has long been known to offset many of the effects of ∆9-THC. The very 
first report came in the mid-70s when Karniol and colleagues administered oral tablets 
of both ∆9-THC and CBD to healthy volunteers. In this study co-administration of CBD 
significantly reduced the heart-rate increase, time-distortion and psychological effects 
of ∆9-THC (Karniol et al., 1974). A few years later, the same group showed that CBD 
also reduced the anxiogenic effects of an oral dose of ∆9-THC (Zuardi et al., 1982). 
More recently, Morgan and colleagues investigated the impact that CBD had on 
cannabis used recreationally among healthy cannabis users. They analysed participants 
hair samples for cannabinoids and found that individuals who were positive for ∆9-
THC-only had experienced significantly more psychotic like experiences compared to 
the participants who were positive for both ∆9-THC and CBD (Morgan and Curran, 
2008).  
Similar results were found in a large Dutch population based study, where participants 
were asked in an online survey which type of cannabis they preferred smoking. Since 
the sale of cannabis is tolerated in the Netherlands, this allows government bodies to 
carry out annual analyses on the cannabinoid content of the various types sold. In the 
survey, the authors found that users who preferred cannabis types high in CBD had 
fewer lifetime psychotic experiences (Schubart et al., 2011). Lastly, and possibly the 
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clearest examples of CBD’s ability to inhibit the psychotogenic effects of ∆9-THC, was a 
small pilot-study administering ∆9-THC and CBD to 6 healthy volunteers intravenously. 
1.25mg IV ∆9-THC significantly increased psychotic symptoms, while this was 
significantly reduced by co-administration of 5mg IV CBD (Morrison et al., 2010). 
Intravenous studies 
In order to study specific drug mechanisms and interactions, it is vital to minimise any 
source of variability in bioavailability of the compounds being tested. Cannabis is most 
commonly smoked as cigarettes or ingested orally. Naturalistic studies exploring the 
effects of recreational cannabis use on various outcomes benefit from allowing the 
participant to smoke or ingest the drug in a manner as similar to real life as possible 
(Morgan, Schafer, et al., 2010). One drawback however is that there are significant 
inter-individual differences in drug absorption from both oral and smoked routes of 
administration. For smoked cannabis, factors such as duration of smoking, puff 
duration, volume inhaled, smoking skill, lung capacity and loss of side-stream smoke 
may affect bloodstream cannabinoid concentration (Lindgren et al., 1981; Perez-Reyes 
et al., 1982). Orally consumed cannabinoids (either via capsules or food items) suffer 
from poor and irregular absorption (Grotenhermen, 2003), and are pharmacologically 
the least reliable. It is estimated that about 50% of the cannabinoids are lost due to 
stomach acids (Perez-Reyes et al., 1973). Intravenous administration on the other hand 
provides the most reliable delivery of synthetically prepared cannabinoids, with low 
inter-individual variability in drug plasma concentrations (Ohlsson et al., 1981). The 
plasma profile following an intravenous dose approximates that from the inhalational 
route (Ohlsson et al., 1981) where concentrations fall rapidly due to redistribution. 
Further reductions, attributable to drug metabolism, progress at a slower rate. Table 1 













There is wide variation and individual reactions to IV ∆9-THC. This is illustrated by IV 
studies administering high doses of ∆9-THC to healthy volunteers, and observing 
psychotic symptoms, anxiety, and dysphoria. Volkow and colleagues  administered a 
2mg IV dose of ∆9-THC to 8 healthy volunteers, of whom two became anxious and one 
became paranoid (Volkow et al., 1991). In a study Morrison and colleagues, 50% of 
participants experienced increased positive psychotic symptoms following a 2.5mg IV 
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∆9-THC dose (Morrison et al., 2009). D’Souza and colleagues administered 2.5mg and 
5mg IV ∆9-THC to both healthy volunteers and clinically stable schizophrenic patients. 
They observed that 35% of the controls and 80% of the patients displayed psychotic 
symptoms following 2.5mg, while 50% of controls and 75% of patients did so after 5mg 
(D’Souza et al., 2005). Jointly, these observations suggest that about 35-50% of the 
psychiatrically healthy general population are susceptible to psychotomimetic effects 
and anxiety experienced from high doses of ∆9-THC. Conversely, this means about half 
the general population are in some way resilient towards these effects. One possible 
explanation to this may be that these individuals have a naturally higher level of 
endocannabinoid activity. It has been previously shown that schizophrenic patients 
which higher levels of CSF anandamide are less symptomatic (Giuffrida et al., 2004) 
and prodromal patients with high anandamide transition into psychosis later (Koethe 
et al., 2009).  
Although the intravenous route of administration has clear benefits in terms of 
elucidating precise pharmacological effects and interactions, it does suffer limitations 
in terms of how generalisable it is when drawing conclusions about cannabis use. 
Cannabis is commonly smoked with tobacco and titrated to achieve desired effects (T. 
P. Freeman et al., 2014), although a recent study has found that this may be more 
difficult with higher potency products (van der Pol et al., 2014). In studies which 
administer an intravenous bolus the participant is unable to titrate the dose of the 
cannabinoids resulting in a dose which is not compatible to the one he/she would use 
recreationally. Furthermore, studying the effects of cannabis in a laboratory 
environment may fail to provide ecological validity as the setting may feel unnatural or 
intimidating to the participant (Morgan, Schafer, et al., 2010). Lastly, cannabis which is 
ingested orally has a vastly different metabolism which results in increased levels of 
psychoactive metabolites (eg. 11-OH-∆9-THC and 7-OH-CBD) compared to inhaled or 
IV, which may result in a different psychopharmacological effect (Ohlsson et al., 1981).  
Aims 
In this thesis I aim to explore the psychological, cognitive, and electrophysiological 
effects of different cannabinoids in healthy volunteers, making use of the intravenous 
administration route to ensure minimal variation in bioavailability of ∆9-THC. I will do 
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this across two separate studies. The first study will pre-treat participants with either 
CBD or placebo before IV administration of 1.5mg ∆9-THC. The psychological and 
cognitive effects of this study will be presented separately to the electrophysiological, 
in different chapters. The second study will pre-treat volunteers with ∆9-THCV or 
placebo before administration of 1mg IV ∆9-THC. I hypothesise that CBD and ∆9-THCV 
will significantly reduce the psychotomimetic and cognitively impairing effects of IV ∆9-
THC, and that 1mg ∆9-THC will have less negative effects compared to 1.5mg. 
Furthermore, I predict that CBD will significantly reduce ∆9-THC-induced 





Cognitive and psychological effects of ∆9-THC and CBD 
Pre-article introduction 
CBD was first isolated in the 1930s and its structure was elucidated in 1963 by 
Mechoulam and colleagues (Mechoulam and Shvo, 1963). In a study comparing the 
effects of smoked cannabis or pure ∆9-THC, the authors noted there being a 
qualitative difference between the two smoked preparations (Galanter, 1973). This 
was later confirmed in both animal and human studies, which seem to suggest that 
other components of the cannabis plant interact with ∆9-THC and change its effects 
(Carlini et al., 1974). The first study to compare the effects of pure CBD and ∆9-THC in 
humans took place in 1974, where oral doses of ∆9-THC (30mg) were combined with 
increasing doses of CBD (15mg, 30mg, and 60mg) (Karniol et al., 1974). They found 
that CBD was able to reduce the heart rate increase and time-underestimation 
produced by ∆9-THC, while also producing fewer unpleasant experiences. In a 
subsequent study 1mg/kg CBD significantly reduced the anxiety produced by 0.5mg/kg 
∆9-THC when given orally, further suggesting CBD acts in an inhibitory fashion against 
∆9-THC.  
As will be mentioned in the article below, more recent naturalistic studies have found 
that cannabis products which contain higher levels of CBD are less psychotogenic and 
cognitively impairing (Morgan and Curran, 2008; Schubart et al., 2011). 
Epidemiological studies have also suggested that cannabis with higher CBD content 
poses less risk of psychosis (Di Forti et al., 2009). As previously mentioned, orally or 
inhaled ∆9-THC suffers from unpredictable absorption and irregular inter-individual 
bioavailability (Grotenhermen, 2003). The aim of the below study is to explore the 
protective effects of CBD on ∆9-THC induced paranoia, psychosis and memory 
impairment, making use of IV ∆9-THC administration to reduce inter-individual 
bioavailability.  
The initial plan of the below study was to use an intravenous administration for both 
∆9-THC and CBD, although the license to import IV CBD had expired and we were 
forced to use oral CBD instead. Oral CBD goes through first pass metabolism and may 
result in significantly higher levels of its metabolites (Harvey and Mechoulam, 1990), 
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which may serve as a confound if they are pharmacologically active or interfere with 
the pharmacology of CBD and  ∆9-THC. Furthermore, the method of using two modes 
of administration (oral and intravenous) lacks ecological validity, as a user would be 
exposed to both cannabinoids simultaneously when either inhaling or ingesting 
cannabis.  
The choice of the dose for oral CBD (600mg) was based on previously shown anxiolytic 
(Bergamaschi et al., 2011) and anti-psychotic effect (Leweke et al., 2012), as well as 
preliminary pharmacokinetic data from a previous study (Bhattacharyya et al., 2010). 
The dose of IV ∆9-THC (1.5mg) was based on previous studies from our lab (Morrison 
et al., 2009, 2011; Barkus et al., 2011) where both the 1.25mg and 2.5mg doses 
significantly impaired cognition and induced psychotic symptoms, the latter dose being 
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Abstract 
Community-based studies suggest that cannabis products that are high in Δ9-
tetrahydrocannabinol (∆9-THC) but low in cannabidiol (CBD) are particularly hazardous 
for mental health. Laboratory-based studies are ideal for clarifying this issue because 
∆9-THC and CBD can be administered in pure form, under controlled conditions. In a 
between-subjects design, we tested the hypothesis that pre-treatment with CBD 
inhibited ∆9-THC-elicited psychosis and cognitive impairment. Healthy participants 
were randomised to receive oral CBD 600mg (n=22) or placebo (n=26), 210 min ahead 
of intravenous (IV) ∆9-THC (1.5 mg). Post-∆9-THC, there were lower PANSS positive 
scores in the CBD group, but this did not reach statistical significance. However, 
clinically significant positive psychotic symptoms (defined a priori as increases ≥3 
points) were less likely in the CBD group compared with the placebo group, odds ratio 
(OR)=0.22 (χ2=4.74, p<0.05). In agreement, post-∆9-THC paranoia, as rated with the 
State Social Paranoia Scale (SSPS), was less in the CBD group compared with the 
placebo group (t=2.28, p<0.05). Episodic memory, indexed by scores on the Hopkins 
Verbal Learning Task-revised (HVLT-R), was poorer, relative to baseline, in the placebo 
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pre-treated group (-10.6±18.9%) compared with the CBD group (-0.4%±9.7 %) (t=2.39, 
p<0.05). These findings support the idea that high-∆9-THC/low-CBD cannabis products 
are associated with increased risks for mental health.  
Introduction 
The cannabis plant contains over 60 different cannabinoid molecules(Izzo et al., 2009), 
but two in particular have relevance for psychiatry. Δ9-tetrahydrocannabinol can 
induce acute psychotic symptoms, in medicated schizophrenic patients and in healthy 
controls, whereas cannabidiol (CBD) is showing promise as a possible anti-psychotic 
(D’Souza et al., 2009; Leweke et al., 2000; Zuardi et al., 2006).  
The balance of these two molecules in ‘street cannabis’ appears to have changed over 
the last decade. For example, in the UK and Holland, cannabis products traditionally 
contained about 4% ∆9-THC and 4% CBD, as compared with 16–22% ∆9-THC and <0.1% 
CBD content in modern ‘high-potency’ products (Sinsemilla or ‘skunk’) (Slade et al., 
2012). There is accruing evidence that sinsemilla carries a greater risk to mental health 
(Di Forti et al., 2009; Morgan and Curran, 2008; Schubart et al., 2011).  
In a highly original design, Morgan and Curran measured trace cannabinoid levels in 
hair samples from regular cannabis users as well as psychosis proneness as rated by 
the OLIFE (Oxford Liverpool Inventory of Life Experiences) instrument. Regular users 
who were grouped as ∆9-THC-positive/CBD-negative scored higher on scores of 
unusual experiences than regular users who were positive for both cannabinoids 
(Morgan and Curran, 2008). In an epidemiological study in South London, Di Forti and 
colleagues compared patterns of drug use in people presenting with a first episode of 
psychosis with healthy controls. Patients were approximately seven times more likely 
than controls to be users of sinsemilla (Di Forti et al., 2009).  
In Holland, the most popular types of cannabis sold are measured annually for ∆9-THC 
and CBD content. Schubart and colleagues combined this information with data on 
cannabis use from approximately 1900 people, and found that the ∆9-THC/CBD ratio 
was related to subclinical psychotic experiences as rated by the CAPE scale 
(Community Assessment of Psychic Experiences). Subjects who used products with a 
high ∆9-THC/CBD ratio reported significantly higher CAPE-total scores than those using 
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products with a low ∆9-THC/CBD ratio. In heavy users, higher CBD content was 
associated with lower scores on the CAPE-positive symptoms dimension (Schubart et 
al., 2011).  
In laboratory-based experimental studies, the acute effects of specific cannabinoid 
molecules can be measured under tightly controlled conditions. For example, in the 
early 1980s, Zuardi and colleagues demonstrated that CBD (1 mg/kg) inhibited the 
anxiety provoked by ∆9-THC (0.5 mg/kg) (Zuardi et al., 1982). More recently, in a 
neuroimaging study of 15 healthy volunteers, task-specific blood-oxygen-level-
dependent (BOLD) responses were measured following the administration of oral ∆9-
THC (10 mg), CBD (600 mg) or placebo. Relative to placebo, ∆9-THC and CBD evoked 
diametrically opposite task-specific BOLD responses in the hippocampus, the amygdala 
and the occipital cortex (Bhattacharyya et al., 2010), the right superior temporal gyrus 
(Winton-Brown et al., 2011) and the pre-frontal cortex and caudate nucleus 
(Bhattacharyya et al., 2012).  
Previously we reported preliminary findings that pre-treatment with intravenous (IV) 
CBD (5 mg) inhibited IV ∆9-THC (1.25 mg) evoked positive psychotic symptoms, as 
measured by the Positive & Negative Syndrome Scale (PANSS), although the small 
sample size (crossover, n=6) prevents definitive conclusions (Morrison et al., 2010). 
Here we report the first findings from a larger study (between groups, n=48) in which 
IV ∆9-THC (1.5 mg) followed pre-treatment with either oral CBD (600 mg) or placebo. 
We hypothesised that, following IV ∆9-THC, the group who had been pre-treated with 
CBD would show less positive symptoms and less cognitive impairment than the group 
that had been pre-treated with placebo.  
Methods 
The study was approved by the Joint Institute of Psychiatry and Maudsley Hospital 
Ethics Committee. All subjects provided written informed consent. Safety protocols 






In a 2×3 mixed design, participants were randomly allocated in a counterbalanced 
fashion to placebo or CBD groups. Placebo/CBD capsules were administered under 
double-blind conditions. Each participant was assessed at three separate time-points: 
(1) baseline; (2) post-capsule; and (3) post-∆9-THC. (Baseline data were collected on a 
separate day at least 1 week before the experimental day.)  
Participants 
A total of 48 participants were recruited via the King’s College e-mail lists. Inclusion 
criteria were: age between 21 and 50 years, previous cannabis use ≥1. Detailed 
screening was performed 1–2 weeks before the experimental session. In addition to 
clinical examination, the following screening tools were used: The MINI-SCID, The 
Michigan Alcohol Screening Test and The Drug Addiction Screening Test (Gavin et al., 
1989; Selzer et al., 1975; Spitzer et al., 1992). Exclusion criteria were: current 
pregnancy, a history of mental illness, drug or alcohol dependence (excluding 
nicotine), current or past severe medical disorders or a history of major mental illness 
in a first-degree family member. Previous alcohol and drug use were recorded and a 
urine drug screen was carried out. Participants were asked to avoid alcohol (for 24 h) 
and drugs (for 1 week) before, and to abstain from driving for 24 h after the 
experimental session. Pregnancy tests and urine drug tests were used on each study 
visit to exclude recent drug use or pregnancy in women. Experimental sessions began 
between 9–10 am and were complete by 4–5 pm. Participants received a brief clinical 
examination prior to discharge, a ‘check-up’ phone call the following day and were 
reimbursed for their time.  
Pharmaceuticals 
Cannabidiol (2×300 mg capsules) and matching placebo were obtained from STI 
Pharmaceuticals UK. Synthetic ∆9-THC was supplied by ∆9-THC Pharm GmbH 
(Frankfurt am Main, Germany) and prepared as 1 mg/mL vials for IV injection, by 
Bichsel Laboratories (Interlaken, Switzerland) as previously described (Naef et al., 
2004). After dilution in normal saline, preparations for injection contained 1.5% (v/v) 
ethanol absolute. Sterile cannulae were inserted into veins in the antecubital fossa of 
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both arms: one for administration of ∆9-THC and one for plasma sampling. ∆9-THC was 
administered in 1 mL/min pulses over a period of 10 mins (total dose 1.5 mg). Blood 
samples were taken at 1 h, 2 h, 3 h 45 min (5 min post-∆9-THC), 4 h 10 min (30 min 
post-∆9-THC) and 5 h (80 min) post capsule. Doses of oral CBD and IV ∆9-THC were 
selected on the basis of previous studies (Bhattacharyya et al., 2010; D’Souza et al., 
2004; Morrison et al., 2009; Zuardi et al., 2006). Capsules (placebo/CBD) were 
administered 3 h 30 min prior to IV ∆9-THC challenge, based on the available (albeit 
limited) knowledge regarding the pharmacokinetics of CBD (Bhattacharyya et al., 
2010).  
Psychopathological and cognitive measures 
Baseline predictive instruments 
Prior to the experimental session, participants completed the following questionnaires 
online: the Green et al. Paranoid Thoughts Scale (GPTS) Part B, which provides a 
measure of trait paranoia (Green, Freeman, Kuipers, Bebbington, Fowler, Dunn, and P. 
A. Garety, 2008); the Cannabis Experiences Questionnaire (CEQ), which quantifies 
psychotic/dysphoric experiences following recreational cannabis use (Barkus and 
Lewis, 2008); and the Schizotypal Personality Questionnaire (SPQ) (A. Raine, 1991). 
This permitted assessment of whether measures of ‘psychosis-proneness’ differed 
between the two groups. Participants also completed the Wechsler Test of Adult 
Reading (WTAR), which provides an estimate of IQ (Wechsler, 2001).  
Experimental measures 




Table 2.1. The time-course of the experimental day. Participants were instructed to 
report/score their experience based upon the peak intensity within the time-window 






Under CBD/placebo and ∆9-THC conditions, participants were instructed to 
report/score their experience based upon the peak intensity within the time-window 
since the previous drug administration.  
Positive psychotic symptoms 
The positive psychotic dimension was assessed using two instruments: the PANSS (Kay 
et al., 1987) (Appendix I) as described previously (Morrison et al., 2009), and The State 
Social Paranoia Scale (SSPS) (Freeman et al., 2007) (Appendix II). The PANSS was 
developed for schizophrenia research and consists of a positive subscale (seven items: 
delusions, conceptual disorganisation, hallucinations, hyperactivity, grandiosity, 
suspiciousness and hostility), a negative subscale and a general subscale. Items are 
rated from 1–7 (absent–severe), thus the range on the positive subscale is 7–49. There 
is a wide inter-individual variation in PANSS positive scores following ∆9-THC and, as a 
group, positive symptoms are modest compared with acute schizophrenia. In earlier 
studies approximately 35–50% of healthy participants showed changes of ≥3–4 points 
(D’Souza et al., 2004; Morrison et al., 2009). The SSPS is a participant-rated instrument 
consisting of 10 persecutory items (e.g. ‘Someone wanted me to feel threatened’), 
embedded within neutral and positive items. Responses are rated 1–5 (do not agree–
totally agree). The SSPS has excellent internal reliability, adequate test-retest 
reliability, convergent validity with both independent interviewer ratings and self-
report measures, and divergent validity with regard to measures of positive and 
neutral thinking (Freeman et al., 2007).  
Affect 
The University of Wales Mood Adjective Checklist (UMACL) (Appendix III) was used to 
assess affect (Matthews et al., 1990). The UMACL is sensitive to change in the three 
major dimensions of affect: Hedonic Tone (pleasure–displeasure); Energetic Arousal 
(awake–tiredness); and Tense Arousal (tension–relaxation). On each dimension, 
participants rated their level of agreement with four positive and four negative 
adjectives. Scores within each dimension were summed to give a value between -12 




Three of the four tasks that were employed make up part of the MATRICS Consensus 
Cognitive Battery (MCCB, PAR, Inc FL 33549) (exception: Digit span). Alternative 
versions of each task were used across the three different conditions, (baseline, post-
capsule, post-∆9-THC), except for symbol-coding. All participants encountered each 
version in a consistent order. For each of the three conditions, cognitive tasks were 
presented in the following sequence (under ∆9-THC conditions, cognitive testing began 
at 40 min post-∆9-THC injection).  
The Hopkins Verbal Learning Task-Revised (verbal learning and memory) 
In the Hopkins Verbal Learning Task-Revised (HVLT-R) (Appendix IV), participants are 
tested in their immediate recall of 12 words (nouns from three taxonomic categories) 
after each of three learning trials. Here, delayed recall was assessed 20–25 min after 
the final learning trial.  
Symbol coding (processing speed) 
This is a timed pencil-and-paper task in which participants are required to translate a 
symbol into a corresponding digit (1–9), whilst a reference key of symbol/digit pairs 
remains visible (Appendix V).  
Digit-span forward and reverse (working memory) 
The digit span task (forward-condition) (Appendix VI) evaluates the capacity of working 
memory. Participants are tested for immediate recall of a sequence of digits; and given 
two attempts at each level of difficulty. In the reverse digit span condition, participants 
are required to recall the sequence in the reverse order, which places additional 
processing demands on working memory.  
Neuropsychological Assessment Battery mazes (planning and organisational abilities) 
In the Neuropsychological Assessment Battery (NAB) mazes (Appendix VII), 
participants are scored on a composite measure of accuracy and speed in a series of 
seven progressively more difficult maze-tracing tasks. Since only two equivalent 
versions are available, this task was only presented at the post-capsule and post-∆9-




All analyses were performed in SPSS 17.0 (SPSS Inc., Chicago). PANSS and SSPS data did 
not have a normal distribution and were analysed after log transformation as 
described previously (Kleinloog et al., 2012). In addition, for the PANSS we followed 
the approach of D’Souza and colleagues, which is to categorise clinically significant 
psychosis as increases from baseline of ≥3 points (D’Souza et al., 2005): thereafter the 
difference in the frequency of clinically significant ∆9-THC-evoked psychotic reactions 
between the CBD and placebo groups was analysed using Pearson’s Chi-square. 
Normally distributed data were analysed by a general linear model (GLM), specifically 
repeated-measures ANOVA. The within-groups factor was CONDITION (1. Baseline 2. 
Post-capsule 3. Post-∆9-THC). The between-groups factor was pre-treatment GROUP 
(1. CBD 2. Placebo). Greenhouse–Geisser statistics were used in cases where sphericity 
assumptions were violated. Post-hoc analyses were performed with Bonferroni 
correction. Relationships between psychosis scores and cognitive data were analysed 
using Spearman’s rank correlation coefficient. Significance was accepted at p values 
<0.05. All comparisons were two-tailed.  
Results 
In total, 48 subjects completed the experimental protocol (Placebo group n=26; CBD 
group n=22). In three subjects, failure of cannulation prevented the administration of 
∆9-THC, and data acquired up to that point were not used in any of the analyses. The 
two groups were adequately matched for demographic variables, baseline measures of 
‘psychosis-proneness’ and previous drug use (Table 2.2). Previous cannabis exposure 
between the two groups was not significantly different whether data were analysed by 




Table 2.2. Sample characteristics at baseline. The two groups (CBD & placebo) were 
adequately matched for demographic variables, ‘psychosis-proneness’ as indexed by 
the SPQ (Schizotypal Personality Questionnaire;), CEQ (Cannabis Experiences 
Questionnaire), Green et al. Paranoia Scale, BMI (Body Mass Index), and for previous 




The plasma concentrations of CBD and ∆9-THC over time are shown in Figure 2.1. 
Plasma concentrations of CBD were highest at the 3 h 45 min testing point, before 
beginning to decrease. ∆9-THC concentrations were not significantly different between 
the group pre-treated with CBD and the group pre-treated with placebo at 5 min 




Figure 2.1. Plasma cannabinoid concentrations (mean±SEM). Oral CBD (600 mg) was 
administered at 0 min. ∆9-THC (1.5 mg) was administered by slow IV injection from 
210–220 min. In the CBD pre-treated group and the placebo pre-treated group, 
differences in plasma ∆9-THC concentrations at three successive sampling points were 
not statistically significant. With respect to ∆9-THC administration, plasma [∆9-THC] 
was assayed at 5, 30 and 80 min post-injection.  
 
Positive psychotic symptoms 
PANSS-positive scores 
There was a main effect of CONDITION (F=27.9, p<0.000), but no effect of GROUP 
(F=1.7, p=0.19) and no interactive GROUP×CONDITION effect (F=2.28, p=0.14) (Figure 
2.2). In the placebo group, PANSS positive scores, (mean±sd) increased by 2.4 (±3.1) 
points following ∆9-THC, compared with 1.2 (±1.8) in the CBD group, a non-significant 
difference (t=1.5, p=0.15) (Figure 2). Clinically significant positive symptoms following 
∆9-THC, defined as an increase in PANSS positive scores of ≥3 points, were more 
common in the group pre-treated with placebo (11 of 26 cases) compared with the 
group pre-treated with CBD (3 of 22 cases), (χ2=4.74, p<0.05) (Table 2.3).  
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Figure 2.2. Pre-treatment with Cannabidiol, CBD (600 mg po) versus placebo reduced 
IV ∆9-THC (1.5 mg) elicited increases in PANSS positive scores (mean±SEM), but 





Table 2.3. Pre-treatment with cannabidiol, CBD (600 mg po) reduced the odds of 
developing a clinically significant acute psychotic reaction to IV ∆9-THC (1.5 mg), 
defined as a ≥3-point increase from baseline on the PANSS positive subscale.  
 
SSPS scores 
There was a main effect of CONDITION (F=7.5, p<0.005), but no effect of GROUP 
(F=2.5, p=0.12). There was a CONDITION×GROUP interaction (F=4.7, p<0.05) (Figure 
2.3). The increase in SSPS scores post-∆9-THC, with respect to baseline, was greater in 




Figure 2.3. Pre-treatment with cannabidiol, CBD (600 mg po) inhibited IV ∆9-THC (1.5 
mg) evoked paranoia, as measured by the SSPS (mean ±SEM). The increase in SSPS 
scores [post-∆9-THC minus baseline] was greater in the placebo versus the CBD group 




There were no main effects of CONDITION (F=1.5, p=0.23), GROUP (F=0.001, p=0.98) 
and no interactive CONDITION×GROUP effects (F=0.23, p=0.74).  
Energetic arousal 
There was a main effect of CONDITION (F=19.2, p<0.000) but no effect of GROUP 
(F=0.07, p=0.80) and no interactive CONDITION×GROUP effects (F=1.32, p=0.23). 
Energetic arousal decreased in the CBD group following the administration of CBD 
(p<0.01), whereas subsequent decreases following ∆9-THC were not significant 
(p=0.13). Energetic arousal also decreased in the placebo group, at the level of a trend 
following the administration of placebo (p=0.08), whereas subsequent decreases 





There was a main effect of CONDITION (F=28.5, p<0.000) but no effect of GROUP 
(F=0.003, p=0.98) and no interactive CONDITION×GROUP effects (F=0.58, p=0.50). 
Tense arousal increased following the administration of ∆9-THC in both groups (CBD 
group, p<0.005, placebo group, p<0.000).  
Cognition 
Scores on the cognitive battery at baseline, post-CBD/placebo, and post-∆9-THC are 
shown in Table 2.4.  
Table 2.4. Under ∆9-THC (IV 1.5 mg) conditions, cognitive performance was generally 
poorer, except for the Symbol coding and NAB-MAZES tasks. ∆9-THC-elicited deficits in 





The Hopkins Verbal Learning Task 
Immediate recall 
There was a main effect of CONDITION (F=22.64, p<0.000) but no effect of GROUP 
(F=0.079, p=0.78) and no interactive CONDITION×GROUP effects (F=0.92, p=0.88). 
Immediate recall was poorer following ∆9-THC, regardless of group. Post-hoc analysis 
revealed differences between post-∆9-THC and baseline performance, significantly in 
the placebo group (p<0.005), and at the level of a trend in the CBD group (p=0.06). 
Differences between post-∆9-THC and post-capsule performance were significant in 
the CBD group (p<0.000) and the placebo group (p<0.005). Following ∆9-THC, 
immediate recall was 2.9 (±5.3) and 3.6 (±4.5) items fewer in the CBD and placebo 
groups, respectively, compared with baseline, a non-significant between-groups 




Figure 2.4. (a) Immediate recall in the HVLT-R (mean±SEM) was poorer following IV ∆9-
THC (1.5 mg), in both the placebo and CBD (600 mg po) pre-treated groups. (b) 
Delayed Recall was poorer following ∆9-THC in the placebo but not the CBD pre-
treated group. Relative to baseline, performance under ∆9-THC was poorer in the 
placebo compared to the CBD group (t=2.39, p<0.05). HVLT-R, The Hopkins Verbal 




There was a main effect of CONDITION (F=7.25, p<0.005), but no effect of GROUP 
(F=1.75, p=0.19). There was a trend towards a CONDITION×GROUP interactive effect 
(F=3.26, p=0.058). Post-hoc analysis in the placebo-group revealed differences 
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between post-∆9-THC and baseline (p<0.05) and between post-∆9-THC and post-
capsule performance (p<0.05). Corresponding analyses in the CBD group were p=1.0 
and p=0.6, respectively. Following ∆9-THC, delayed recall decreased from baseline by 
10.6% (±18.9%) in the placebo group and by 0.4% (±9.7) in the CBD group, a significant 
between-groups difference (t=2.39, p<0.05), (Figure 2.4(b)).  
A posteriori, we explored if there were relationships between impaired delayed recall 
and positive psychotic symptoms, post ∆9-THC. In the placebo group, poorer delayed 
recall was related to the magnitude of PANSS-positive symptoms, at the level of a 
trend (Spearman’s rho=0.3, p=0.09). The relationship between poorer delayed recall 
and higher scores on the SSPS was stronger and reached significance (Spearman’s 
rho=0.5, p<0.05); corresponding findings in the CBD group were -0.3, p=0.9 and 0.5, 
p<0.05).  
Symbol coding 
There was a main effect of CONDITION (F=11.12, p<0.000) but no effect of GROUP 
(F=0.003, p=0.98) and no interactive CONDITION×GROUP effects (F=0.53, p=0.82). 
Performance improved in both groups from the baseline condition to the post-∆9-THC 
condition, (CBD group p<0.01; placebo group p<0.05).  
Digit-span forward 
There was a main effect of CONDITION (F=7.38, p<0.005) but no effect of GROUP 
(F=0.44, p=0.51) and no interactive CONDITION×GROUP effects (F=1.24, p=0.30). Post-
hoc analysis in the placebo group revealed significant differences between digit-span 
performance in the post-∆9-THC condition compared with both the baseline (p<0.05) 
and post-capsule conditions (p<0.05). Corresponding post-hoc analyses in the CBD-
group were p=1.00 and p=0.08, respectively.  
Digit-span reverse 
There was a main effect of CONDITION (F=9.46, p<0.000) but no effect of GROUP 
(F=0.000, p=0.99) and no interactive CONDITION×GROUP effects (F=1.53, p=0.86). 
Post-hoc analysis in the placebo group revealed differences between reversed digit-
span performance in the post-∆9-THC condition compared with the baseline (p=0.08) 
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and post-capsule conditions (p<0.05). Corresponding post-hoc analyses in the CBD-
group were p=0.5 and p<0.01, respectively.  
Mazes 
There were no main effects of CONDITION (F=2.1, p=0.15), GROUP (F=2.4, p=0.13) and 
no interactive CONDITION×GROUP effects (F=0.015, p=0.90). Numerical differences 
between groups post-∆9-THC compared with baseline were not different (t=0.13, 
p=0.9).  
Discussion 
Our major findings are that pre-treatment with CBD inhibited ∆9-THC-induced 
paranoia and inhibited the detrimental effects of ∆9-THC on episodic memory. In 
addition, CBD decreased the proportion of participants who experienced clinically 
significant acute ∆9-THC psychosis.  
Cannabinoids and psychosis 
The majority of community-based studies that have addressed the issue of specific 
cannabinoid components and psychosis have proposed that cannabis products lacking 
CBD are more psychotogenic than products that contain CBD (Di Forti et al., 2009; 
Morgan and Curran, 2008; Schubart et al., 2011); (but see (Morgan, Schafer, et al., 
2010)). The findings in the present study provide strong support for this idea. Here, on 
the PANSS (an investigator-rated scale), clinically significant ∆9-THC psychosis was less 
likely under CBD versus placebo conditions, and on the SSPS (a participant-rated scale) 
∆9-THC-induced paranoia was inhibited under CBD conditions. It is notable that there 
was a trend for higher trait paranoia in the CBD compared with the placebo group, 
suggesting that the CBD group might have been more prone to paranoia at baseline. 
Post-∆9-THC however, there was no apparent rise in paranoia in the CBD group, 
whereas by way of contrast, the placebo group reported significant paranoid 
symptoms.  
Some caution is required, however, with regard to scores on the PANSS positive scale. 
Although the mean PANSS positive score in the CBD group was less, differences did not 
reach statistical significance. Lack of statistical power may be important, but it is also 
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clear that CBD (in so far as it was administered here) does not completely abolish ∆9-
THC-induced positive psychotic symptoms.  
Cannabinoids and memory 
Cognitive performance was poorer following ∆9-THC specifically in the domains of 
working and episodic memory, which is in keeping with previous reports (reviewed in 
(Ranganathan and D’Souza, 2006; Solowij and Michie, 2007). Here, pre-treatment with 
CBD ‘protected’ episodic memory from the impact of ∆9-THC, whereas working 
memory remained ‘vulnerable’ to a similar degree.  
This result is in broad agreement with a study carried out by Morgan and Curran: 
volunteers were assessed at home under the influence of their own chosen type of 
cannabis, a sample of which was subsequently tested for ∆9-THC and CBD content; 
higher levels of CBD in the cannabis used appeared to protect against impairments in 
immediate and delayed prose recall (Morgan, Schafer, et al., 2010). The reason for the 
differences with regard to immediate recall is unknown, but may stem from the 
different tasks employed.  
Here there were marked performance deficits post-∆9-THC in three tests which 
require pre-frontal resources: immediate recall, digit-span forward and digit-span 
back. CBD did not appear to attenuate ∆9-THC-induced deficits in any of the three 
tasks. This contrasted with the protective effect of CBD on delayed recall and paranoid 
symptoms. It is also notable that ∆9-THC-induced impairment in delayed recall and ∆9-
THC-induced paranoia were correlated, and it is feasible that both measures load onto 
a common factor.  
Mechanisms 
Molecular neuropharmacology 
The molecular neuropharmacology of ∆9-THC is well understood: partial-agonism at 
CB1 receptors. Although this may be the most relevant pharmacological property of 
∆9-THC, many other actions have been identified including agonism of the orphan 
receptor GPR55, decrease uptake of adenosine, reduced conductance of ligand-gated 
ion channels of 5-HT3, activation of PPAR-γ, increased uptake of noradrenaline and 
55 
 
decreased uptake of 5-HT (for review see Pertwee, 2008). For CBD, the picture is more 
obscure. In an attempt to shed some clarity on the issue, McPartland and colleagues 
(2014) performed a systematic review of the various pharmacological actions of CBD. 
Out of eight CBD efficacy studies at the CB1 receptor found no response while the 
other two found opposing and weak effects at high concentrations. Also, CBD has very 
poor affinity to the CB1 receptor after pooling the results of fifteen studies. However, 
six studies found CBD to be a potent antagonist of CB1 agonist at very low 
concentrations. Put together these results indicate that CBD acts via an indirect 
mechanism to inhibit ∆9-THC and other agonists compared to a classical antagonist 
which has affinity for the orthosteric site (McPartland et al., 2014). CBD also has many 
other pharmacological actions. Five studies found that CBD inhibits anandamide 
breakdown by FAAH and four studies found that it inhibits reuptake of anandamide via 
a putative transporter. CBD agonises orphan receptors GPR18 and antagonises GPR55, 
both which opposes the actions of ∆9-THC. Twelve studies found CBD to activate 
transient receptor potential ion channels (e.g. TRPV1, TRPV2, TRPA1, TRPM8). Seven 
studies have shown that CBD can modulate intracellular calcium levels, a mechanism 
which also triggers anandamide production. It has also been found that CBD inhibits 
the reuptake of adenosine (3 studies), positive allosteric modulation of α3 glycine (3 
studies), PPAR-γ activation (5 studies), and reduces production of nitric oxide (15 
studies. A further twelve studies support the notion of CBD as an allosteric modulator 
of receptor systems such as α1-adrenoceptors, dopamine D2, GABAA, µ- opioid and δ-
opiod receptors. It remains unclear as to which of these pharmacological actions are 
involved in the inhibitory actions of CBD on ∆9-THC and further in vitro work will be 
required to identify which action underlies a particular psychopharmacological effect, 
at the systems and the behavioural levels.  
Systems pharmacology 
How ∆9-THC impacts upon episodic memory is reasonably well understood. Episodic 
memory depends upon the integrity of hippocampal circuitry. Numerous animal 
studies have shown that CB1 agonists disrupt processes within the hippocampus that 
are believed to be at the heart of learning and memory – network oscillations, 
neuronal synchrony and plasticity (Fan et al., 2010; Hájos et al., 2000; Holderith et al., 
2011; Robbe and Buzsáki, 2009). Recently, CB1 agonists have become a useful tool in 
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hippocampal research. This is because CB1 agonists disrupt synchronicity, without 
altering the firing rates of individual neurons in the network – a unique property 
amongst drugs which impact on hippocampal function (Robbe et al., 2006).  
The mechanisms underlying the pro-psychotic properties of ∆9-THC are less well 
understood. Theoretical accounts have invoked excessive, pathological dopamine 
release (Kuepper et al., 2010; Murray et al., 2007), but experimental support for this 
has been weak (Barkus et al., 2011; Bossong et al., 2009; D’Souza, Braley, et al., 2008; 
Kleinloog et al., 2012; Stokes et al., 2009) (but see (Liem-Moolenaar et al., 2010)). 
Other accounts have focussed on disrupted network oscillations (Sewell et al., 2009). 
Here the experimental evidence has been stronger (Morrison et al., 2011; Stone et al., 
2012) but remains at an early stage.  
In the present dataset, we were interested by the apparent relationship between ∆9-
THC psychosis and ∆9-THC-elicited impairments in episodic memory. However, the 
presence of such a relationship was not hypothesised a priori, and replication is 
required.  
Strengths and limitations 
In laboratory-based pharmacological studies, pure synthetic preparations can be 
administered at a set dose under controlled conditions. This is particularly relevant for 
cannabinoid studies because ‘street cannabis’ contains a multitude of other molecules, 
many of which are known to be pharmacologically active. One example is Δ9-
Tetrahydrocannabivarin (∆9-THCV), a CB1 receptor antagonist at low doses, an agonist 
at higher doses (Pertwee, 2008). Compared with ‘street cannabis’, pure synthetic 
preparations are ideal for studying the behavioural pharmacology of specific 
cannabinoid molecules, because pharmacodynamic and pharmacokinetic influences 
from other constituents can be disregarded from the outset. A limitation in the present 
study is that only one dose of CBD was investigated. Future studies could examine if 
higher CBD doses, or indeed extended dosing over several days, produce stronger 






Previous epidemiological and experimental studies have suggested that cannabis 
products lacking CBD are more psychotogenic than products containing CBD. The 
findings here provide strong support for this view. Under controlled experimental 
conditions, CBD decreased ∆9-THC-elicited positive psychotic symptoms and 
‘protected’ hippocampal-dependent memory from the impact of ∆9-THC.  
Post-article comments 
In this study, although CBD significantly inhibited ∆9-THC-induced paranoia, 
impairments to delayed verbal recall and reduced the proportion of clinically 
significant psychosis; CBD did not completely abolish the psychotogenic effects of ∆9-
THC nor protects against working memory impairment. Subjectively, all participants 
experienced intoxication following ∆9-THC, although this was not measured in a 
standardised way which precludes inferences about the effects of CBD on the 
subjective effects of IV ∆9-THC. Also, it is not possible to determine if the individuals 
who experienced psychosis in the CBD group would be protected from a higher dose of 
CBD. Alternatively, it is possible that passed a certain dose of ∆9-THC, CBD becomes 
ineffective. To clarify this, future studies would benefit from exploring a range of doses 
for both ∆9-THC and CBD. 
An interesting finding was that of a trend towards a group difference between the CBD 
and placebo groups in terms of scores on the Green Paranoid Thoughts scale, where 
the CBD group scored higher. This has potential implications in terms of the specific 
protective role of CBD towards paranoid thoughts. A recent study found that 
individuals predisposed to paranoid thinking were more susceptible to the paranoia 
inducing effects of ∆9-THC (D. Freeman et al., 2014). Since there was no significant 
increase in paranoia in the CBD group following THC, in spite of them being slightly 
more predisposed to begin with, it may suggest that CBD has a particularly strong anti-
paranoid effect.  
Pleasure is one of the main reasons for the recreational use of cannabis. Although we 
did not include this data in the manuscript, it was collected for this study. Data was 
collected on a 5-point likert scale on the item: “This experience is pleasurable”. There 
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was a significant main effect of CONDITION (F=37.591, p<0.001) but no effect of 
GROUP (F=0.118, p=0.73) or a CONDITIONxGROUP interaction (F=0.065, p=0.937). 
Post-hoc analysis revealed a significant increase in pleasure scores between post-
capsule and post-THC in both the placebo (p<0.001) and CBD groups (p<0.001), but no 
difference between the groups at the post-THC time point (p=0.983). This indicates 
that CBD does not significantly affect the pleasurable effects of THC, which could be 
important from a public health perspective. As the most frequent users grow tolerant 
to THC and require larger quantities to achieve the same level of intoxication 
(Desrosiers et al., 2015), this may lead them to consuming cannabis with greater THC 
content which may subsequently be more harmful (Di Forti et al., 2009, 2013). This 
finding may suggest that cannabis products with a high THC and high CBD content may 
still be preferred by frequent users as CBD does not interfere with the pleasurable 
effects of cannabis, and may be less harmful compared to cannabis containing only 
THC. 
Although ∆9-THC significantly impaired performance on working memory tasks such as 
forward and reverse digit-span and immediate verbal recall, performance on speed-of-
processing and executive function tasks (symbol recoding and mazes task) were not 
affected. Previous studies have found that some areas of cognition are less impaired 
by ∆9-THC (Pope et al., 1995; Ramaekers et al., 2006a). These results further 
strengthen the notion that ∆9-THC impacts on processing speed and executive 
function less compared to other cognitive domains.  
The choice to exclude participants who were currently or previously dependent on 
cannabis may have impacted the result of this study. Previous studies have shown that 
frequent users are more resilient to the acute cognitive (Hart et al., 2010) and 
psychotogenic (D’Souza, Braley, et al., 2008) effects of ∆9-THC. This is likely due to 
tolerance built up from frequent and repeated use of cannabis, as well as  
downregulation of the brains CB1 receptors (Hirvonen et al., 2012). Conversely, 
individuals sensitive towards the acute effects of ∆9-THC who also have had 
unpleasant experiences from cannabis are unlikely to volunteer in research. This may 
also have confounded the results of this study by including participants who were 
more resilient towards ∆9-THC. Luckily, both groups were equally matched on the 
paranoia/dysphoria measure of the CEQ (which indicates previous unpleasant 
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experiences while using cannabis) as well as number of use occasions, suggesting no 
group differences in possible resilience towards ∆9-THC.  
Apart from only using one dose of CBD being a limitation of this study, so was the oral 
administration of CBD. Ideally, CBD should have been administered intravenously 
which would have allowed an interpretation of the CBD/∆9-THC ratio which is less 
harmful. In a previous pilot-study, Morrison and colleagues administered 5mg IV CBD 
before 1.25mg IV ∆9-THC and found that CBD protected against positive psychotic 
symptoms (Morrison et al., 2010); a CBD/∆9-THC ratio of 4. However, plasma levels of 
CBD were stable among participants, and ∆9-THC was administered at peak CBD levels.  
Another possible limitation to the study was the use of a between subjects design. 
Similar to previous studies with IV ∆9-THC (D’Souza et al., 2004; Morrison et al., 2009), 
there was great individual variability of reactions to ∆9-THC, where just over 40% of 
participants experienced paranoia and psychosis. To better capture the protective 
effects of CBD, the same individual would be given the same dose of IV ∆9-THC twice, 
co-administered with either CBD or placebo. However, the participant number in this 




Electrophysiological effects of ∆9-THC and CBD 
Introduction 
As discussed earlier, the two main components of cannabis are ∆9-
tetrahydrocannabinol (∆9-THC) and cannabidiol (CBD). It is well established that ∆9-
THC is the main cannabinoid responsible for the psychological effects of cannabis, and 
given in higher doses is able to induce psychotic symptoms and memory impairments 
similar to that of schizophrenia (D’Souza et al., 2004; Morrison et al., 2009). CBD on 
the other hand has been shown to reduce the anxiety inducing effects (Zuardi et al., 
1982), psychotic symptoms (Morgan and Curran, 2008; Morgan et al., 2012; Englund et 
al., 2013), and memory impairing effects of ∆9-THC (Morgan, Schafer, et al., 2010; 
Englund et al., 2013). ∆9-THC acts as a partial agonist at the CB1 receptor, while the 
pharmacological actions of CBD are less clear and include such pharmacological effects 
as acting as a 5HT1A agonist, adenosine reuptake inhibition, TRPV1 agonist, GRP55 
agonist, and causing increased intra-cellular calcium (Izzo et al., 2009). Although these 
effects are likely to play a part in reducing the negative effects of ∆9-THC, other 
pharmacological actions are more likely. It is known that CBD has a direct inhibitory 
effect on CB1 agonists, and in several ways (increased calcium, endocannabinoid 
reuptake inhibition, inhibition of FAAH) causing increased endocannabinoid levels 
which may compete with ∆9-THC (Pertwee, 2008).  
The CB1 receptors are densely populated in the main areas of the brain related to the 
effects of cannabis: hippocampus, neocortex, cerebellum and basal ganglia (Glass et 
al., 1997). The endocannabinoid system regulates synaptic weight in these regions by 
producing and releasing endocannabinoids from GABAergic and glutamatergic post-
synaptic terminals following activation of these terminals (increased intracellular 
calcium) (Fernandez-Espejo et al., 2009). As the endocannabinoid system is finely 
tuned to the rhythms of the network, it is likely that exogenous cannabinoids such as 
∆9-THC may fail to mimic this effect and instead disrupt the network in a dose 
dependent manner.  
Studies recording neural activity using electroencephalography (EEG) are well 
equipped to capture changes to precise firing of neural networks as EEG provides 
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excellent temporal resolution on a millisecond scale. However, the interpretation of 
EEG is limited as electrical activity is recorded merely from the scalp which makes 
interpretation of the origins of the oscillations difficult. Furthermore, EEG is vulnerable 
to interfering artefacts produced by ocular movements and scalp muscles tensions 
which can distort the recording or make interpretation difficult (Croft and Barry, 2000; 
De Vos et al., 2010).  
Studies from the past decades have highlighted the importance of neural oscillations in 
higher order functions such as memory, synaptic plasticity, attention, perception, 
motor control and consciousness (Uhlhaas et al., 2008; Buzsáki and Draguhn, 2004). 
EEG activity is divided into 5 main frequency bands: Delta (0-3.5Hz), Theta (3.5-7Hz), 
Alpha (8-13Hz), Beta (14-25Hz) and Gamma (30-200Hz). Network oscillations result 
from the synchronised firing of large assemblies of neurons, which also constrain the 
firing of individual neurons to the rhythms of the network (Buzsáki and Draguhn, 2004; 
Varela et al., 2001). This synchronised activity helps strengthen network connections 
(long term potentiation) (Pavlides et al., 1988), as well as aiding rapid short (gamma) 
and long-distance (alpha, beta, theta) communication between brain regions (Kopell et 
al., 2000; von Stein et al., 2000).  
Several animal studies have highlighted the importance of the endocannabinoid 
system in regulating and maintaining neural oscillations. Such studies benefit from the 
ability to insert electrodes into specific areas of interest of the brains of the animals or 
alternatively relevant brain areas may be removed from the animal and tested in vitro. 
Hajos and colleagues showed that gamma oscillations in the CA3 area of the 
hippocampus were significantly reduced following administration of a selective CB1 
agonist. The authors concluded that activation of presynaptic CB1 receptors reduced 
the power of hippocampal oscillations by exerting inhibition of GABA release (Hájos et 
al., 2000). In a similar in vitro study, release of endocannabinoids interrupted 
hippocampal theta rhythms in the CA1 region of the hippocampus (Reich et al., 2005). 
An in vivo study in anesthetized freely moving rats showed that administration of the 
potent CB1 agonist CP55940 significantly reduced theta and gamma power in the 
hippocampus (Hajós et al., 2008). This effect was associated with reduced auditory 
sensory gating, a phenomenon which has been linked to abnormal information 
processing (Freedman et al., 2003), and was blocked by co-administration of a CB1 
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antagonist. Kucewicz and colleagues measured electrophysiological changes produced 
by administration of CP55940 while the rats were performing cognitive tasks. They 
reported a significant decrease in hippocampal theta and co-occurring prefrontal 
gamma following drug administration. These effects were also correlated with 
impaired cognitive performance on a spatial working memory task (Kucewicz et al., 
2011). Furthermore, a study administering ∆9-THC and CP55940 to rats reported 
impaired performance during a memory task which was correlated with reduced 
hippocampal theta but not gamma (Robbe et al., 2006). Reductions in power were also 
associated with reduced temporal synchronicity, which the authors conclude may 
underlie the cognitively impairing effects of exogenous cannabinoids. 
Most electrophysiological studies of cannabinoids in humans have examined the 
effects of cannabis (either the acute effects of cannabis or comparing chronic users to 
non-users) on event related potentials (ERPs). Such studies have consistently shown a 
reduction of amplitude of ERPs, often in a dose dependent manner, during acute 
intoxication with ∆9-THC (D’Souza et al., 2012; Spronk et al., 2011; Greenwood et al., 
2014; K B E Böcker et al., 2010); the effects were significantly less pronounced in more 
frequent users (Theunissen et al., 2012; Hart et al., 2010). Two studies further explored 
the differences between ∆9-THC and combination of ∆9-THC and CBD on ERPs. They 
showed that CBD had no significant impact on ∆9-THC-induced P300 reductions (Roser 
et al., 2008), but also that the combination of CBD and ∆9-THC increased the mismatch 
negativity (MMN) ERP while this was unchanged during ∆9-THC and placebo conditions 
(Juckel et al., 2007). 
Studies investigating differences between users and non-users on EEG power have 
observed reduced power among users (Skosnik et al., 2006), which also correlated with 
age of onset of use (Skosnik et al., 2012). Ilan and colleagues measured EEG after 
participants smoked a standardised cannabis cigarette containing either 0% or 3.45% 
∆9-THC. They reported reduced theta power after ∆9-THC compared to placebo across 
the scalp, as well as reduced alpha reactivity during increased difficulty on the working 
memory task. These effects coincided with reduced accuracy and slower response 
times on the working memory task, as well as increased false-positive responses on an 
episodic memory task (Ilan et al., 2004). In a subsequent study by the same group, EEG 
effects of low and high dose ∆9-THC (1.8% and 3.6%) co-administered with either low 
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or high dose CBD (between 0.1-0.4% and greater than 1%) were investigated. Although 
∆9-THC reduced alpha, beta, and theta power and impaired working and episodic 
memory performance following both doses of ∆9-THC, there was no significant 
protective effect of CBD (Ilan et al., 2005). The dose dependent effect of ∆9-THC on 
EEG power was further explored by Böcker and colleagues (Koen B E Böcker et al., 
2010). They had participants smoke cannabis cigarettes containing 29.3mg, 49.1mg, 
and 69.4mg ∆9-THC and observed a dose response reduction in theta and beta power. 
Furthermore, a greater decrease in theta power coincided with slower response times 
on a working memory task. 
As mentioned previously, inhaled or orally administered ∆9-THC suffers from great 
inter-individual variation in bioavailability (Grotenhermen, 2003), which is why the 
intravenous route of administration is preferred. In a novel study, Morrison and 
colleagues explored the effects of intravenous ∆9-THC on EEG power and coherence (a 
measure of temporal synchronicity between scalp locations) (Morrison et al., 2011). 
They also measured performance on a working memory task and psychotic symptoms 
as measured by the PANSS. ∆9-THC significantly increased psychotic symptoms and 
slowed reaction time compared to placebo, while also significantly reducing theta 
power, and theta coherence between bi-frontal electrode regions. There was a 
significant correlation between the reduction in bi-frontal theta coherence and 
positive psychotic symptoms on the PANSS scale. In a subsequent study, Stone and 
colleagues explored the relationship between changes to frontal inter-trial coherence 
(ITC, a measure of synchronised oscillations during the 150ms preceding speech) and 
psychotic like symptoms following intravenous ∆9-THC. ITC was significantly reduced 
by ∆9-THC and was correlated with measures of salience and ipseity disturbance 
(Stone et al., 2012). Studies comparing differences between healthy volunteers and 
patients with schizophrenia have observed reductions in EEG power and synchronicity, 
similar to what has been observed in ∆9-THC studies (Ford et al., 2002; Ford and 
Mathalon, 2008; Uhlhaas et al., 2008). 
The human literature on EEG effects of ∆9-THC has consistently observed reductions to 
theta power and synchronicity, where these reductions correlate with poorer 
performance on cognitive tasks and increases in psychotic symptoms. In the following 
study I will explore the potential protective effect of CBD on ∆9-THC-induced changes 
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to EEG amplitude and coherence. I hypothesise that ∆9-THC will significantly reduce 
theta amplitude and coherence, and that these reduction will be inhibited by CBD. 
Furthermore, reduction in theta coherence will correlate with positive psychotic 
symptoms.  
Methods 
The study was approved by the Joint Institute of Psychiatry and Maudsley Hospital 
Ethics Committee. All participants were given at least 24 hours to study the participant 
information sheet and provided written informed consent. Participants were informed 
that they could withdraw from the study at any time for any reason and that all 
information relating to their participation would be kept anonymous. They were 
informed of potential adverse effects of intravenous ∆9-THC (short-lived feelings of 
anxiety and psychosis-like symptoms), and that rescue medication (Lorazepam 1-4mg) 
would be made available in case participants so wished. 
Design 
This was a randomized, double-blind, placebo-controlled, between subject study in 
which 600mg oral Cannabidiol or matched placebo as a pre-treatment before 
intravenous administration of 1.5mg ∆9-THC. The timeline for the study is presented in 
Table 3.1. Participants were first invited for a screening visit. During this visit a brief 
medical screening was performed, participants were evaluated for eligibility, 
consented to the study and baseline assessment of cognitive and psychopathology 
scales were performed. At the end of the screening visit the participants were booked 
in for an experimental session and told to avoid all drug use until the end of the study, 
and avoid alcohol 24 prior to the experimental session. Participants were asked to 
have a normal breakfast, but informed that no caffeinated beverages would be 
allowed on the day. The experimental session started with baseline EEG recordings, 
following which the participant was administered either placebo or CBD. A 2 hour 
break followed to allow for absorption of CBD, based on previous pharmacokinetic 
data (Bhattacharyya et al., 2010; Zuardi et al., 2006). This was followed by the post-
capsule EEG recordings, cognitive and psychological assessments. Participants were 
then infused with intravenous ∆9-THC over 10 minutes, which was followed by post-
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∆9-THC EEG, cognitive and psychological testing. Once all testing had been completed, 
the participants stayed in the lab until the effects of ∆9-THC had worn off, which took 
approximately three hours. Participants were followed-up the day after via telephone 
in order to make sure there were no delayed negative effects of the drug. Only one 
participant reported mild sedative effects which wore off after a few days. 
Table 3.1. Experimental timeline 
 
Participants 
Forty eight healthy male and female participants were enrolled to the study via circular 
email to King’s College staff and students and word of mouth.  Participant 
demographics are presented in Table 3.2. Three were excluded from the final EEG 
analysis due to incomplete or noisy EEG recordings. Inclusion criteria were healthy 
male and female volunteers aged between 21-50 years. Exclusion criteria included 
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being cannabis naïve, history of mental illness (psychotic disorder, depression, 
anxiety), past treatment with psychotropic medication, major physical illness, major 
mental illness in first degree family member, history of alcohol or substance misuse 
(excluding tobacco) and currently pregnant. Pregnancy tests and urine drug tests were 
used on each study visit to exclude recent drug use or pregnancy in women. All 
participants provided written informed consent. 
Table 3.2. Participant demographics 
 
Pharmaceuticals 
CBD (2 x 300mg) capsules and matching placebo were provided by STI Pharmaceuticals 
UK. Synthetic ∆9-THC was acquired from STI Pharmaceuticals UK, via ∆9-THC Pharm 
GmbH (Frankfurt am Main, Germany) and prepared as 1 mg/mL vials for IV injection, 
by Bichsel Laboratories (Interlaken, Switzerland). 1.5mg ∆9-THC was diluted in 8.5ml 
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normal saline in a 10ml syringe. ∆9-THC was administered over 10 minutes with 1ml of 
the solution being injected each minute.  
Cognitive and Psychological measures 
Baseline predictive measures 
Participants provided demographic information and completed the Green et al 
Paranoid Thought Scale (part B, trait paranoia) (Green, Freeman, Kuipers, Bebbington, 
Fowler, Dunn, and P. a Garety, 2008), Schizopytal Personality Questionnaire (SPQ) ( a 
Raine, 1991), Cannabis Experience Questionnaire (CEQ) (Barkus and Lewis, 2008), 
Wechslers Test for Adult Reading (WTAR) (Wechsler, 2001) at the start of the study. 
These scales were used to compare the two groups on levels of trait paranoia (GPTS), 
psychosis-proneness (SPQ), cannabis and drug use history as well as levels of 
paranoid/dysphoric experiences during cannabis use (CEQ), and levels of pre-morbid 
IQ. There were no significant differences between the CBD and placebo groups on any 
of these measures (Table 3.2.).  
N-Back task 
The n-back task has been widely used as a working-memory (WM) task in a variety of 
neuroimaging studies (Owen et al., 2005) (Example playlist in Appendix VIII). The tasks 
place increasingly greater demand on many aspects of WM as it requires participants 
to monitor, update, remember and manipulate information as the task becomes more 
difficult.  In this study participants performed the n-back task while EEG was recorded. 
For the n-back task participants are asked to monitor a series of letters appearing on a 
computer monitor in front of them, and asked to respond whenever a letter is the 
same as one presented n trials previously, as quickly as possible. The task starts with 
the 0-back condition which requires the participant to respond whenever the letter X is 
presented. This is followed by the 1-back, 2-back and lastly 3-back condition; each 
subsequent condition being more difficult and requires greater cognitive effort. 
Participants were sat at eye-level ~66cm from a CRT monitor and instructed to make 





Positive And Negative Syndrome Scale (PANSS) 
The PANSS is a validated investigator rated measure of positive (delusions, 
hallucinations, suspiciousness, hyperactivity, conceptual disorganisation, and hostility) 
negative and general psychotic symptoms used mainly for schizophrenia research (Kay 
et al., 1987). Each item is scored on a 7 point scale from absent (1) to severe (7). To 
assist scoring each point level of each item has a description of the characteristics of 
the scoring. PANSS was assessed at baseline, post-capsule, and post-∆9-THC. The post-
∆9-THC PANSS was performed after the main psychoactive effects of ∆9-THC had 
started to wear off, so that possible ∆9-THC-induced feelings of paranoia and anxiety 
towards the researchers would not lead the participant to withhold information 
regarding their feeling states. In fact, retrospective accounts from previous studies 
(Morrison et al., 2009) have indicated that participants may feel distrust towards 
researchers while under the influence of ∆9-THC, hence reporting no significant 
change in mood or thoughts. 
State Social Paranoia Scale (SSPS) 
The SSPS is a 20-item self-rated scale which consists of 10 neutral items and 10 items 
asking questions relating to state paranoia and persecutory thinking (Freeman et al., 
2007). Each item is scored on a 5-point scale ranging from ‘do not agree’ to ‘totally 
agree’. Participants were asked to rate the scale according to what they had been 
feeling and thinking within the last 20 minutes. For the ∆9-THC session, participants 
were asked to rate the scale based on the peak intensity of the ∆9-THC-experience. 
Electroencephalography 
Neuroscan 4.3 was used for all data acquisition and processing in this study. A 64 
electrode Quick-Cap Systems (Compumedics) EEG cap was used for the recording of 
EEG data. The recording reference electrodes were place on both earlobes, data was 
re-referenced to average mastoid electrodes, and the ground was connected at AFz. 
Impedances were kept below 10 kΩ by adding additional conductive gel to the 
electrodes and relocating the participant’s hair at the site of the electrode to achieve a 
better connection. Additional electrodes were placed above and below the left eye of 
the participants to measure vertical electrooculographic (EOG) activity, as well as 
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electrodes on the outer canthi to measure horizontal EOG. The EEG was recorded at a 
5000 Hz sampling rate, and was down-sampled to 1000 Hz before processing. Major 
noise to the EEG trace was manually removed, and eye-blinks were corrected using the 
data from the horizontal and vertical EOG. The data was then baseline corrected and 
epoched using a 10% Hanning window into 2.048 second sections from 24ms before to 
2024ms after each presentation of an n-back letter. Average amplitude was calculated 
within the frequency bands delta (1-3.5 Hz), theta (3.5-7 Hz), alpha (8-13 Hz), beta (14-
25 Hz), gamma (30-40Hz); using Fast Fourier Transform for each of the four n-back 
conditions. For the amplitude analysis, electrodes were grouped into the following 
regions: left frontal (LF), right frontal (RF), left central (LC), right central (RC), left 
temporal (LT), right temporal (RT), left occipito-parietal (LOP), right occipito-parietal 
(ROP) (see Table 3.3) (for EEG electrode location see Figure 3.1). Electrodes FZ, CZ, and 
PZ were analysed individually. 




Figure 3.1. Location of EEG electrodes. 
 
Coherence refers to a measure of correlation of EEG activity between two scalp 
locations for a specific frequency band, and consists of a value ranging from 0 to 1 
(Pearson’s correlation equivalent). For the analysis of coherence, data was 
transformed to bipolar derivations of pairs of neighbouring electrodes at two 
locations: Left-frontal (F3/F5) and right-frontal (F4/F6). Coherence was measured for 
each n-back condition between bi-frontal (F3/F5- F4/F6) electrode pairs. 
Statistical analysis 
All statistical analyses were performed in SPSS 21 (IBM, N.Y.). Similarly to previous 
studies (D’Souza et al., 2005; Englund et al., 2013), a clinically significant psychotic 
reaction was defined as an increase of 3 or more points on the PANSS positive sub-
scale. Pearson’s Chi-squared test was used to compare group differences in frequency 
of clinically significant psychosis. Due to floor effects on both the PANSS and SSPS, 
Friedman’s non-parametric test was used to assess differences in scores across 
sessions. Mann-Whitney U tests were used to analyse differences between CBD and 
placebo groups. Accuracy and reaction time on the N-back task was assessed using 
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repeated measures ANOVA, with Session (Baseline, Post-Capsule, Post-∆9-THC) and 
Load (0-back, 1-back, 2-back, 3-back) as within subjects factor, and Treatment (CBD, 
Placebo) as between subjects factor. For EEG amplitude, repeated measures ANOVA 
were used for each frequency band (delta, alpha, theta, beta, low gamma, high 
gamma). The within-subject factors were Location (LF, RF, LC, RC, LT, RT, LOP, ROP, FZ, 
CZ, PZ), Session (Baseline, Post-Capsule, Post-∆9-THC), working memory Load (0-back, 
1-back, 2-back, 3-back), and Treatment (Placebo, CBD) as between-subjects factor. 
Similarly, repeated measures ANOVA were used for EEG coherence with Session 
(Baseline, Post-Capsule, Post-∆9-THC) and working memory Load (0-back, 1-back, 2-
back, 3-back) as within-subjects factors, and Treatment (Placebo, CBD) as between-
subjects factor. Log-transformations were implemented where data was not normally 
distributed, and Huynh-Feldt corrected statistics were used where assumptions of 
sphericity were violated. Correlations between changes to EEG coherence and 
psychopathology were done using Spearman’s rho. The changes in scored on the 
PANSS, SSPS and EEG coherence were calculated as the difference between post-
capsule and post-∆9-THC testing points. Post hoc analyses and multiple comparisons of 
correlations were Bonferroni corrected. All analyses were two-tailed and significance 
levels were accepted at p<0.05. 
Results 
Cognition and psychology 
N-back 
Accuracy (as a percentage of correct responses) on the N-back task did not significantly 
change following ∆9-THC (Session: F=2.261, p=0.118). There was a significant reduction 
in performance as the task got harder (Load: F=73.888, p<0.001), and there was a 
trend towards a Session x Load interaction (F=2.324, p=0.075). CBD did not affect 
performance (Treatment: F=0.662, p=0.421), and there was no significant Session x 
Treatment effect (F=1.019, p=0.358) (Figure 3.2). 
Reaction time on the n-back task was significantly increased across sessions (Session: 
F=6.352, p=0.003). ∆9-THC only increased reaction time on a trend level compared to 
baseline (p=0.075), while this was not significant when comparing to the post-capsule 
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session (p=0.921). As the task got harder, reaction time significantly increased (Load: 
F=76.589, p<0.001). CBD did not influence reaction time (Treatment: F=2.366, 
p=0.133), and there was no Session x Treatment interaction (F=1.326, p=0.272) (Figure 
3.3). 
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PANSS  
In the placebo group 11 out of 24 participants had a clinically significant psychosis, 
while only 3 out of 21 in the CBD group reached this threshold (2=5.201, p=0.028). 
However, when comparing raw PANSS scores both the placebo group (2=26, p<0.001) 
and the CBD group (2=19.149, p<0.001) showed significant increases across sessions. 
There was no significant difference between the placebo and the CBD group at the 
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SSPS 
There was a significant increase in paranoia scores on the SSPS across sessions in the 
placebo group (2=16, p<0.001), but not in the CBD group (2=1, p=0.607). There was a 
significant difference between CBD and placebo groups at the post-∆9-THC session (Z=-





















Alpha amplitude significantly decreased with greater difficulty of the n-back task (Load: 
F=56.179, p<0.001), where 2-back (p<0.001) and 3-back (p<0.001) were significantly 
reduced compared to lower loads. There were significant differences in alpha 
amplitude with regards to scalp Location (F=64.017, p<0.001), where the amplitude 
was greatest at occipio-parietal locations (LOP, ROP, PZ, p<0.001) compared to other 
locations (Figure 3.6).  
∆9-THC and CBD effects 
Amplitude significantly increased after each subsequent testing point (Session: 
F=18.403, p<0.001), where alpha significantly increased from baseline to post-capsule 
(p<0.001) and from post-capsule to post-∆9-THC (p<0.001). This suggests that alpha 
amplitude increased as an effect of time rather an effect of ∆9-THC. However, the 
increased alpha amplitude between post-capsule and post-∆9-THC was only significant 
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in the placebo group (p<0.001), while this was non-significant in the CBD group 
(P=0.651). ∆9-THC significantly influenced alpha increase differently according to scalp 
location (Location x Session: F=4.462, p=0.001), where ∆9-THC increased alpha 
increase at frontal and temporal locations while reducing alpha increase at central 
locations (Figure 3.7). CBD on its own did not influence alpha (F=0.003, p=0.958), and 
there was no significant Session x Treatment effect (F=1.23, p=0.286) (Figure 3.8). 
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There was a significant decrease in beta amplitude as the n-back task became more 
difficult (Load: F=88.898, p<0.001), with amplitude being significantly lower during 2-
back (p<0.001) and 3-back (p<0.001) compared to lower loads. Beta amplitude did not 
significantly differ across scalp locations (Location: F=1.993, p=0.085) (Figure 3.9). 
∆9-THC and CBD effects 
∆9-THC significantly increased beta amplitude (Session: F=15.53, p<0.001), and the 
increase from post-capsule to post-∆9-THC was significant for both the placebo 
(p<0.001) and CBD group (p<0.001). ∆9-THC also affected the influence of WM load on 
amplitude (Session x Load: F=2.761, p=0.026), where the difference between 1-back 
and 2-back was significant at the post-capsule testing point (p=0.002) and non-
significant post-∆9-THC (p=0.184). ∆9-THC significantly influenced beta increase 
differently according to scalp location (Location x Session: F=11.622, p<0.001), where 
the increase was greatest at temporal locations (Figure 3.10). CBD did not significantly 
affect beta amplitude (Treatment: F=0.482, p=0.491), and did not influence ∆9-THC-
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WM effects  
Delta amplitude significantly decreased with greater difficulty of the n-back task 
(F=21.607, p<0.001), 2-back (p<0.001) and 3-back (p<0.001) were significantly reduced 
compared to lower loads. There was a significant effect of scalp location on delta 
amplitude (Location:  F=124.193, p<0.001), where amplitude was significantly greater 
at FZ (p<0.001) and CZ (p<0.001) compared to other locations (Figure 3.12). 
∆9-THC and CBD effects 
There was a non-significant increase of delta amplitude following ∆9-THC (Session: 
F=3.031, p=0.077).  ∆9-THC significantly influenced delta amplitude differently 
according to scalp location (Location x Session: F=6.073, p<0.001), where ∆9-THC-
induced delta increase was greatest at frontal and temporal locations (Figure 3.13). 
CBD did not influence delta amplitude (Treatment: F=0.00, p=0.991), although it 
significantly influenced ∆9-THC-induced delta increase (Session x Treatment: F=3.787, 
p=0.047) (Figure 3.14), where delta was increased between post-capsule and post-∆9-
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Theta amplitude significantly decreased with greater difficulty of the n-back task (Load: 
F=9.069, p<0.001), although theta was only significantly decreased during 3-back 
compared to 0-back (p=0.003) and 1-back (p=0.001). Amplitude significantly differed 
according to scalp location (Location: F=250.612, p<0.001), where amplitude was 
greatest at FZ (p<0.001) and CZ (p<0.001) compared to other locations (Figure 3.15). 
∆9-THC and CBD effects 
There was a significant reduction in theta amplitude following ∆9-THC (Session: 
F=15.723, p<0.001) and the decrease from post-capsule to post-∆9-THC was significant 
for both the placebo (p<0.001) and CBD group (p<0.001). ∆9-THC significantly 
influenced the theta amplitude differently according to scalp location (Location x 
Session: F=8.542, p<0.001), where the decrease was greatest at fronto-central 
locations (Figure 3.16). There was no significant effect of CBD (Treatment: F=1.18, 
p=0.283), and CBD did not influence ∆9-THC-induce theta reduction (Session x 
Treatment: F=2.475, p=0.111) (Figure 3.17). 
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Gamma amplitude was significantly decreased by greater working memory load (Load: 
F=27.635, p<0.001), where 2-back (p<0.001) and 3-back (p<0.001) were significantly 
reduced compared to lower loads. There was a significant difference in amplitude 
across scalp locations (Location: F=27.162, p<0.001), where gamma was greatest at 
frontal and temporal locations (LF, RF, LT, RT: all p<0.05) (Figure 3.18). 
∆9-THC and CBD effects 
∆9-THC significantly increased gamma amplitude (Session: 28.82, p<0.001), where 
amplitude was significantly increased from post-capsule to post-∆9-THC in both the 
placebo (p<0.001), and CBD (p<0.001) group. ∆9-THC significantly influenced gamma 
amplitude differently according to scalp location (Location x Session: F=1.946, 
p=0.048), where the increase was greatest at temporal locations (Figure 3.19). There 
was no significant effect of CBD on gamma (Treatment: F=0.133, p=0.717), and CBD did 
not influence ∆9-THC-induce gamma increase (Session x Treatment: F=0.271, p=0.710) 
(Figure 3.20). 
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Alpha coherence significantly changed across working memory load (Load: F=2.879, 
p=0.043), although none of the post-hoc comparisons were significant. 
∆9-THC and CBD effects 
Bi-frontal alpha coherence was significantly reduced following ∆9-THC (F=3.757, 
p=0.034), although this reduction was only significant between baseline and post-∆9-
THC (p=0.003) and not between post-capsule and post-∆9-THC (p=0.221). However, 
change from baseline to post-∆9-THC was significant only in the placebo group 
(p=0.004) but not in the CBD group (p=0.571). CBD did not significantly change alpha 
coherence (Treatment: F=0.969, p=0.33), and did not influence ∆9-THC-induced 
reduction of coherence (Session x Treatment: F=0.639, p=0.507) (Figure 3.21). 



























Bi-frontal theta coherence significantly increased with greater difficulty on the working 
memory task (Load: F=16.803, p<0.001), where coherence was reduced for 0-back 
compared to all other loads (p<0.05) which did not significantly differ from each other.  
∆9-THC and CBD effects 
∆9-THC significantly reduced bi-frontal theta coherence (Session: F=27.986, p<0.001), 
where coherence was reduced between post-capsule and post-∆9-THC for both the 
placebo (p<0.001) and CBD group (p<0.001). CBD did not significantly influence theta 
coherence (Treatment: F=0.011, p=0.916), and did not influence ∆9-THC-induced 
reduction in coherence (Session x Treatment: F=0.26, p=0.744) (Figure 3.22). 



















Correlations with symptoms 
There was no significant correlation between change in EEG coherence and positive 
psychotic symptoms on the PANSS scale in the theta (rho=0.213, p=0.16) or alpha band 
(rho=-0.075, p=0.626). Furthermore, increases in paranoid symptoms on the SSPS 
following ∆9-THC were not correlated with changes to both alpha (rho=-0.116, 
p=0.331) and theta (rho=0.004, p=0.978) coherence. 
Discussion 
Psychological effects   
Similar to the previous analysis (Englund et al., 2013), exclusion of three participants  
due to poor EEG data did not significantly change the effects of ∆9-THC on 
psychopathology. ∆9-THC increased positive psychotic symptoms and paranoia, but 
this effect was not present in the CBD group, suggesting a protective effect of CBD.  
Cognitive effects 
Although cognitive performance was impaired on certain tasks in the previous analysis, 
there was only a trend towards impaired performance or reduced reaction time on the 
n-back task following ∆9-THC. Furthermore, CBD did not influence performance on the 
n-back task before or after ∆9-THC. 
Theta 
The main frequency band of interest for this study was theta, as previously shown to 
be significantly affected by ∆9-THC (Reich et al., 2005; Hajós et al., 2008; Kucewicz et 
al., 2011; Morrison et al., 2011; Robbe et al., 2006; Ilan et al., 2004, 2005; Koen B E 
Böcker et al., 2010). Particularly Morrison and colleagues who also used intravenous 
∆9-THC, showed significant decreases in theta power and coherence, the latter being 
correlated to positive psychotic symptoms (Morrison et al., 2011). In this study I have 
replicated these findings where both theta amplitude and bi-frontal theta coherence 




I was however unable to find a significant relationship between change in theta 
coherence and increase of positive psychotic symptoms. Interestingly, although CBD 
significantly reduced symptoms of psychosis and paranoia, it did not inhibit ∆9-THC-
induced theta amplitude and coherence reductions. The observation here that theta 
amplitude and coherence were reduced while being unaffected by CBD may suggest 
that theta may not be related to ∆9-THC-induced psychotic symptoms. It has been 
previously demonstrated that theta is related to increased focus and concentration 
(Gevins et al., 1997), which may provide a better explanation for the theta reductions 
in this study. Previous studies have consistently found an association between ∆9-THC-
induced reduced theta and impaired performance on cognitive tasks (Ilan et al., 2004; 
Koen B E Böcker et al., 2010; Kucewicz et al., 2011). However, in this study there was 
only a trend towards poorer accuracy on the n-back task following ∆9-THC, which may 
be explained by a practice effect since the participants had performed the n-back task 
twice before during the same day. Theta reduction may therefore reflect intoxication 
in this instance. Furthermore, CBD alone had no influence on either amplitude or 
coherence, which may suggest that it does not significantly impact normal network 
oscillations. 
Alpha 
There was a significant increase in alpha amplitude across sessions, where the increase 
from baseline to post-capsule was comparable to post-capsule and post-∆9-THC. This 
may suggest an increase as an effect of participants becoming more fatigued as the 
experimental day went on. There was however no increase of alpha in the CBD group 
following ∆9-THC which may be explained as a synergistic effect of ∆9-THC and CBD. 
Juckel and colleagues found that MMN was significantly increased by cannabis extract 
containing both ∆9-THC and CBD, while there was no change under ∆9-THC alone 
(Juckel et al., 2007). They argued that this might indicate a beneficial effect of the 
combination of ∆9-THC and CBD as reduced MMN has been previously been associated 
with schizophrenia (Javitt et al., 1995). This would not seem to be the case in this study 
as there was still an increase of positive psychotic symptoms in the CBD group 
following ∆9-THC, albeit less than in the placebo group.  
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Alpha rhythms are commonly seen in the occipital cortex when the participant’s eyes 
are closed, which is said to reflect cortical networks in “stand-by” (Compston, 2010). 
More recently it has been argued that alpha may be viewed as representing functional 
inhibition of processes which are not related to the task at hand (Sauseng et al., 2007). 
This would seem to fit in with the results from the current study as alpha amplitude 
decreased the more participant’s had to focus on the task (increased WM load), as well 
as alpha increasing for each subsequent testing session (participant fatigue).  
Bi-frontal alpha coherence was significantly reduced following ∆9-THC, an effect which 
was absent in the CBD pre-treated group. Coherence in the alpha band has been 
related to long-distance communication between cortical regions (von Stein et al., 
2000). A reduction in coherence following ∆9-THC may therefore reflect reduced 
communication between frontal regions due to ∆9-THC, resulting in impairments to 
perception and cognition. Similar to amplitude, alpha coherence was not reduced 
following ∆9-THC in the CBD group, which may suggest a protective effect of CBD. 
However, this seems unlikely as alpha coherence was not correlated with positive 
symptoms, as previously demonstrated in a similar study with intravenous ∆9-THC 
(Morrison et al., 2011). Similarly to theta, CBD did not influence alpha amplitude or 
coherence. 
Delta 
There was no significant effect of CBD alone on delta amplitude. However, amplitude 
was significantly increased by ∆9-THC, and this increase was more pronounced in 
frontal and temporal regions compared to other locations. Similar to what was seen in 
alpha, the increase from post-capsule to post-∆9-THC was not observed for the CBD 
group, which suggests that CBD has an inhibitory effect on ∆9-THC-induced delta 
increase. Delta activity is a main component of slow wave sleep, although increases in 
delta during waking states are commonly found in intoxicated, confused and disease 
states. Increased delta power while awake has been observed in delirium (Jacobson 
and Jerrier, 2000), as well as among patients with schizophrenia and their relatives 
(Alfimova and Uvarova, 2007). In this study, I find it unlikely that the ∆9-THC-induced 
delta increase is related to delirium or intoxication as CBD did not affect the 
intoxicating effects of ∆9-THC. As CBD inhibited ∆9-THC-induced delta increase as well 
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as symptoms of psychopathology, it may be argued that the increase in delta observed 
is related to paranoid or psychotic symptoms. However, these findings should be 
interpreted with caution as previous studies with ∆9-THC in humans have either found 
no change in delta (Koen B E Böcker et al., 2010) or a reduction (Morrison et al., 2011). 
Furthermore, increased delta (particularly frontally) may also be an eye movement 
artefact, which might suggest that ∆9-THC increased eye movements.  
Beta 
There was a significant increase in beta amplitude following ∆9-THC which was seen in 
both the placebo and CBD group. ∆9-THC also increased beta amplitude differently 
according to scalp location, where the increase was greatest at temporal regions.  The 
finding that beta was increased by ∆9-THC is contrary to previous ∆9-THC studies 
where generally ∆9-THC has been found to reduce beta (Ilan et al., 2004, 2005; Hart et 
al., 2010; Morrison et al., 2011). However, Böcker and colleagues observed an increase 
in beta for the doses of 29mg and 49mg, while the 69mg dose produced a drop in beta 
power (Koen B E Böcker et al., 2010). Beta activity is commonly considered to be 
related to states of alertness, activity and possibly even anxiety. One study found that 
decreased beta activity was related to feeling more relaxed (Baumeister et al., 2008). 
The disparity between the results of this study with past findings may be explained by 
the higher dose and intravenous administration of ∆9-THC which might have made 
participants feel more anxious or alert compared to previous studies. Furthermore, 
CBD did not change beta amplitude or affect ∆9-THC-induced beta increase. An 
alternative explanation may also be that ∆9-THC made participants clench their jaws 
more and increasing beta amplitude, particularly since the greatest increase was seen 
in temporal locations. 
Gamma 
Similar to beta, gamma amplitude was also significantly increased following ∆9-THC, 
with no protective effects of CBD. This is in line with previous intravenous ∆9-THC 
studies in humans (Morrison et al., 2011), although animal studies have consistently 
shown reductions to gamma in the hippocampus (Hajós et al., 2008; Hájos et al., 2000; 
Kucewicz et al., 2011). These discrepancies may be explained by the use of the more 
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potent CB1 agonists CP55940 which is roughly 45 times as potent as ∆9-THC (Rinaldi-
Carmona et al., 1996), but also that the recoding electrodes were implanted directly 
onto the hippocampus as opposed to mere scalp recordings. Furthermore, scalp 
gamma recordings are vulnerable to a significant amount of artefacts from tonic 
muscle activity, which can be minimised using modern artefact reduction techniques 
(Nottage et al., 2013). Since the main focus of this study is the effects of cannabinoids 
on the lower frequency bands such artefact reductions were not performed, which 
limits the reliability of the findings. Also, similar to beta amplitude gamma may also 
have increased as a result of increased muscle tension of the jaw. 
Mechanisms  
Neural oscillations originate from many different locations depending on frequency, 
including the thalamus, hippocampus, basal ganglia, entorhinal, prefrontal, 
somatosensory, motor, and visual cortex (Uhlhaas et al., 2008). Most of these regions 
come under the control of glutamatergic or GABAergic neurons which regulate 
oscillations, and are also highly innervated with cannabinoid receptors (Howlett et al., 
2002). Disruptions to the finely tuned “on-demand” activity of the endocannabinoid 
system by means of exogenous cannabinoid agonists may therefore result in over-
excitation by glutamate or over-inhibition by GABA. The disrupted, or lack of, 
regulatory input from the endocannabinoid system leads to significant changes to 
normal network oscillations. This is exemplified by a study on CB1-knockout mice 
where several alterations to EEG activity during were observed compared to wild-type 
mice (Silvani et al., 2014).  
The disruptive effects of ∆9-THC on EEG activity in this study are likely due to over-
stimulation of CB1 receptors. This over-stimulation resulted in decreased theta 
amplitude while all other frequency bands increased, also there were significant 
decreases in theta and alpha coherence. In the case of alpha and delta amplitude, CBD 
significantly protected against the amplitude increase. It may therefore suggest that 
CBD acts specifically within these frequency bands while having no impact on others.  
CBD alone did not influence any EEG measure in this study. This is in line with studies 
suggesting CBD acts as an endocannabinoid enhancer, by inhibiting the breakdown or 
reuptake of endocannabinoids (Stern et al., 2012; Bitencourt et al., 2008; Leweke et 
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al., 2012; Capasso et al., 2008). Since the endocannabinoid system does not produce 
and release endocannabinoids until post-synaptic calcium levels have increased (“on-
demand”), increased endocannabinoid levels from CBD would not have an effect until 
the system came under some form of (neural) stress. CBD has been previously shown 
to reduce stress in healthy human volunteers (Crippa et al., 2011; Bergamaschi et al., 
2011), while producing no effects in healthy volunteers without stress (Hollister, 1974; 
Perez-Reyes et al., 1973). In this study only healthy volunteers were recruited, hence 
this may be a population for which CBD has little or no effect on psychological and 
electrophysiological measures. 
Strengths and limitations 
This study benefitted from administering ∆9-THC intravenously as opposed to oral or 
inhaled which significantly reduces inter-individual variation in bioavailability. 
Furthermore, only pure synthetic drugs were used which allows conclusions regarding 
specific pharmacological effects of ∆9-THC and CBD to be drawn. Cannabis extracts of 
smoked cannabis contain a large variety of cannabinoids (with varying concentrations 
of each) and other pharmacologically active components such as terpenoids and 
flavonoids (Russo and McPartland, 2003). 
Due to the high variation in clinical responses to ∆9-THC among healthy volunteers 
(D’Souza et al., 2004; Morrison et al., 2009; Englund et al., 2013), this study may have 
been improved upon by employing a repeated measures design. This would have 
allowed each participant to act as their own control and therefore could have 
improved the power of the study. Furthermore, as the experimental day was very long 
(starting ~9am and finishing ~5pm) and contained repeated sessions of cognitive tasks, 
it is likely this impacted on some of the EEG measurements. This may be potentially 
relevant as participant fatigue could have influenced some of the EEG changes seen 
following ∆9-THC. However, increased theta and decreased alpha were observed 
during working memory which is a highly robust EEG finding for WM tasks (McEvoy et 
al., 2000; Gevins and Smith, 2000; Gevins et al., 1998; Ilan et al., 2004). Furthermore, 
some baseline differences in EEG measures were observed between the two groups 
which may have influenced the results of the analysis. However, post hoc analyses 
revealed no significant differences between baseline measures. 
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Future studies would benefit from employing a repeated measures design to better 
capture the variation in responses to a set dose of ∆9-THC to confirm the findings of 
the current study. Exploring a wider dose-range for both ∆9-THC and CBD would also 
highlight potential dose response effects on measures of cognition, psychology, and 
EEG. Lastly, the length of the experimental sessions should be taken into consideration 
as long testing days with many and demanding cognitive and psychological tasks may 
confound some of the EEG measures. 
Conclusion 
The main findings of this study are that ∆9-THC decreases both theta amplitude and 
coherence, which is in line with previous studies on EEG effects of cannabinoids, 
although an association between these changes and psychopathology was not found. 
Alpha and delta amplitude were significantly increased, but this effect was absent in 
the CBD group which suggests a protective effect against these ∆9-THC-induced 
changes. CBD alone did not influence any EEG measure in this study, which may 




Cognitive and psychological effects of ∆9-THC and ∆9-
THCV 
Introduction 
The effects of cannabis are highly dependent upon the various amounts of the 
different active components of the plant, the cannabinoids (Englund et al., 2013; 
Morgan, Schafer, et al., 2010; Schubart et al., 2011; Zuardi et al., 1982). The Cannabis 
Sativa L. plant produces over 80 different cannabinoids (Izzo et al., 2009). Each 
cannabinoid is produced in various concentrations depending mostly on the specific 
genetic makeup of the individual strain, but also factors such as degrees of lighting, 
temperature and nutrition (Potter, 2013). The main active component of cannabis is 
∆9-tetrahydrocannabinol (∆9-THC) which is the most abundant cannabinoid produced 
by the plant, while the second most common is cannabidiol (CBD) (Potter, 2013). A 
lesser common cannabinoid is ∆9-tetrahydrocannabivarin (∆9-THCV), which often 
exists in very low quantities in most cannabis varieties (Mehmedic et al., 2010). 
However, certain strains of cannabis have been identified which are particularly rich in 
∆9-THCV (Hillig and Mahlberg, 2004).  
Hollister and colleagues were the first to administer pure ∆9-THCV to six healthy 
volunteers. The participants received an intravenous dose of 7mg ∆9-THCV (Hollister, 
1974). One of the participants noticed no effects while the others reported mild to 
moderate cannabis-like effects. The authors concluded that ∆9-THCV is roughly 25% as 
psychoactive as ∆9-THC. ∆9-THCV was initially thought to be a weak agonist at the CB1 
receptor as previous animal studies had indicated (Gill et al., 1970). A more recent 
study highlighted this by demonstrating that the antinociception produced by ∆9-THCV 
was inhibited by the known CB1 receptor inverse agonist SR141716A (Rimonabant) 
(Pertwee et al., 2007). Although it seems as if ∆9-THCV functions as a CB1 agonist, 
there is also evidence that it acts as a CB1 and CB2 antagonist at lower doses (Thomas 
et al., 2005). Furthermore, ∆9-THCV has been shown to inhibit the effects of ∆9-THC in 
mice (Pertwee et al., 2007), while not exhibiting characteristics of a CB1 inverse 
agonist (Rock et al., 2013). This had led researchers to conclude that ∆9-THCV is a CB1 
receptor neutral antagonist (Wargent et al., 2013). A neutral antagonist is a compound 
which binds to a receptor but has 0% efficacy as opposed to an agonist which has at 
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least some efficacy or an inverse agonist which lowers the baseline cellular activity. A 
recent systematic review strengthened this notion as it found that 3 out of 4 efficacy 
studies were consistent with THCV as a neutral antagonist, while the fourth found it to 
be more similar to an inverse agonist (McPartland et al., 2014). Although the precise 
pharmacodynamic profile of THCV has not yet been fully elucidated it appears most 
likely that it acts as a neutral antagonist in the lower dose-ranges, while possibly acting 
as an agonist at higher doses. However, the notion of THCV as an agonist at higher 
doses needs replication as it is merely based on a small sample. 
There remains worry regarding blockade of CB1 receptors in the central nervous 
system as this has been linked to unfavourable psychiatric side effects. Rimonabant, 
which is a CB1 receptor full inverse agonist was marketed as an anti-obesity drug and 
showed very promising results. A meta-analysis found that Rimonabant significantly 
reduced weight (mean 4.7kg over 12months), waist circumference and improved 
cholesterol values (Christensen et al., 2007). However, due to concerns regarding 
significant increase of anxiety, depression and suicidal ideation in the patients treated 
with Rimonabant, the drug was withdrawn from the market (Nissen et al., 2008). More 
recently, studies with Rimonabant in healthy volunteers has shown it to produce a bias 
towards remembering negatively loaded words (Horder et al., 2012) and increasing 
anxiety during a public speaking task (Bergamaschi et al., 2014). CB1 antagonists have 
also shown some indication of improving memory functioning in animals (Shiflett et al., 
2004; Terranova et al., 1996; Lichtman, 2000), although this has not yet been observed 
in humans (Horder et al., 2009; Boggs et al., 2012). 
It has been previously demonstrated that an acute administration of a high dose ∆9-
THC can provoke schizophrenia like psychotic symptoms and cognitive impairment in 
roughly 40-50% of healthy volunteers (D’Souza et al., 2004; Morrison et al., 2009). This 
is particularly relevant as ∆9-THC levels in cannabis sold on the illegal market are on 
the rise (Mehmedic et al., 2010), and globally have roughly doubled since the 1970s, 
with large variation between countries (Cascini et al., 2012). Furthermore, levels of 
CBD, which have been shown to protect against the effects of ∆9-THC (Englund et al., 
2013; Schubart et al., 2011), have either remained low or declining (Potter et al., 2008; 
Mehmedic et al., 2010). 
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Recent studies have highlighted that frequent use of cannabis products high in ∆9-THC 
and low in CBD pose a significantly greater risk of psychosis (Di Forti et al., 2009), as 
well as an earlier onset of the illness (Di Forti et al., 2013). Morgan and colleagues also 
showed that stronger strains of cannabis with less CBD have a greater negative impact 
on memory function (Morgan, Schafer, et al., 2010). In this small pilot study, I report 
the findings of 5 days dosing with ∆9-THCV followed by intravenous administration of 
∆9-THC in 10 healthy male volunteers. I hypothesise that ∆9-THCV will inhibit ∆9-THC 
induced psychotic symptoms, paranoia and cognitive impairment.  
Methods 
The study was approved by the Camden & Islington National Research Ethics 
Committee. All subjects were given time to study the participation sheet and provided 
written informed consent (appendix 1). The safety of intravenous ∆9-THC 
administrations has been previously reviewed (Carbuto et al., 2012). Participants were 
informed of the possibility of short-lived anxious and psychotic like effects of 
intravenous ∆9-THC, and were made aware of stopping procedures of the study as well 
as the possibility of receiving rescue medication (Lorazepam 1-4mg). 
Design 
This was a randomized, double-blind, placebo-controlled, cross-over study in which 
participants were dosed for 5 days with ∆9-THCV or placebo before administration of 
intravenous ∆9-THC. A minimum of two weeks wash out period was allowed between 
each testing week. Consent and screening of participants were carried out on a 
separate occasion prior to the first testing week. The testing weeks consisted of 
baseline assessment on a Monday, which followed administration of either ∆9-THCV or 
placebo. Participants then returned on Tuesday, Wednesday and Thursday for 
additional dosing and monitoring of side-effects. The Friday session started with 
administration of the final dose of ∆9-THCV or Placebo, followed by Post-Capsule 
testing, IV ∆9-THC administration and Post-∆9-THC testing (see Figure 4.1). All 
participants provided a clean urine drugs screen at the start of each testing week, but 
not at the day of the experiment as this would test positive to metabolites of ∆9-THCV 
and unblind the researcher. Vital signs were tested on every visit. 
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Figure 4.1. The timeline of the experimental weeks. The order of assignment to 
placebo or ∆9-THCV treatment was randomised. 
 
Participants 
Ten healthy male volunteers were recruited for this pilot study by means of 
recruitment emails sent to staff and students of King’s College London. Participants 
aged 21-35, with a minimum lifetime cannabis use of at least once and no more than 
25 times were invited for screening and consent. The reason for this narrow inclusion 
criteria of previous cannabis exposure was to try and minimise variation in our sample 
as previous studies have found that frequency of use can affect reactions to THC (Hart 
et al., 2010; D’Souza, Ranganathan, et al., 2008). As funds were limited for this study 
we wanted to keep the sample as homogenous as possible in terms of gender, age and 
past use of cannabis. Exclusion criterion included a history of mental illness (psychotic 
disorder, depression, anxiety), major mental illness in first degree family member (e.g. 
schizophrenia), major physical illness, previous treatment with psychotropic 
medications, past or present drug and alcohol dependence (excluding nicotine) and 
being unable or unwilling to give written informed consent. All participants provided 




Table 4.1. Participant demographics 
 
Pharmaceuticals and Pharmacokinetics 
∆9-THCV (2 x 5mg capsules) and matching placebo were provided by GW 
Pharmaceuticals UK. Synthetic ∆9-THC was acquired from STI Pharmaceuticals UK, via 
∆9-THC Pharm GmbH (Frankfurt am Main, Germany) and prepared as 1 mg/mL vials 
for IV injection, by Bichsel Laboratories (Interlaken, Switzerland).  Oral ∆9-THCV (10mg) 
was administered each day for 5 days to reach steady state plasma concentration of 
∆9-THCV. This was based on recommendations and limited data from GW 
Pharmaceuticals. Intravenous ∆9-THC was prepared as a solution containing 9ml 
normal saline and 1ml ∆9-THC. ∆9-THC was administered over 10 minutes with 
1ml/min pulses (total dose 1mg). For this study we chose a slightly lower dose of IV ∆9-
THC compared to our previous studies (Englund et al., 2013; Morrison et al., 2011; 
Stone et al., 2012; Morrison et al., 2009), to better highlight the possible inhibitory 
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effects of ∆9-THCV in case they are easily overpowered by a high ∆9-THC dose. Blood 
samples to measure plasma cannabinoid levels were taken prior to the administration 
of the final oral tablet (baseline), followed by 5min, 15min, and 1h after the end of 
intravenous ∆9-THC infusion.  Plasma cannabinoid levels were analysed at Quotient 
Bioresearch (Cambridgeshire UK), where ultra performance liquid chromatography – 
tandem mass spectrometry was used for quantification of ∆9-THC, ∆9-THCV, 11-OH-
∆9-THC and 11-OH-∆9-THCV. The lower limit of quantification was 0.25 ng/mg and the 
upper limit of quantification was 250 ng/ml. 
Cognitive tasks 
The Hopkins Verbal Learning Task-Revised 
The Hopkins Verbal Learning Task – Revised (HVLT) is a part of the MATRICS Consensus 
Cognitive Battery (PAR, Inc FL 33549). It consists of learning a list of 12 words across 
three trials (nouns from three taxonomic categories), followed by recall 20-25 minutes 
later, of which there are five validated versions. The versions were randomised 
between each participant and version 1 was used for both baseline testing points. The 
HVLT tests the participants’ performance on immediate and relayed recall, as well as 
taking note of intrusions and repetitions. Immediate recall is measured as the total 
number of words recalled during the three learning trials. Delayed recall is measured 
as the percentage of correctly recalled words compared to the best trial from the 
learning phase. Repetitions refer to number of times a correctly recalled word is 
repeated, and intrusions are words recalled that are related to the words in the list yet 
not part of the original list. 
Digit Span 
The Digit Span refers to the longest list of numbers the participant can correctly recall, 
both in forward and backward order. The task starts at the length of 4 digits and is 
increased by one digit for each successful trial. The task is ended when the participant 






Community Assessment of Psychic Experiences-state (CAPE-state) 
The CAPE-state is a 42-item validated scale which measures positive, negative and 
depressive dimensions of psychotic-like experiences (Stefanis et al., 2002), where each 
item has a yes/no response option. When a yes-response has been given, the 
participant is asked to rate on a 4-point scale how distressing the experience was to 
them. This version of the CAPE produces a frequency score and a distress score for 
each of the different symptom dimensions. 
State Social Paranoia Scale (SSPS) 
The SSPS is a 10-item instrument which measures persecutory thoughts (Freeman et 
al., 2007). The persecutory items (e.g. someone had bad intentions towards me) are 
presented among 10 neutral items and scored on a 5-point scale (0 = Do not agree – 5 
= Totally agree). 
The University of Wales Mood Adjective Checklist (UMACL) 
The UMACL is used to measure the three major dimensions of affect (Matthews et al., 
1990) : Hedonic tone (pleasure-displeasure), Energetic arousal (awake-tiredness), and 
Tense arousal (tension-relaxation). Each dimension consists of four negative and four 
positive adjectives of which the participant scores on a 4-point scale. The scores for 
each dimension are then added up and range from -12 to 12. 
Beck’s Anxiety Inventory 
The Beck’s Anxiety Inventory measures clinical symptoms of anxiety and consists of 20-
items scaled on a 4-point scale (0 = Not at all – 5 = Severely) (Beck et al., 1988). 
Visual analog scale (VAS) 
Visual analog scales were used to measure the following feeling states: ‘high’, ‘calm 
and relaxed’, ‘tired’, ‘anxious’, and ‘stoned’. The scale consists of a 100mm horizontal 
line on which the participant makes a vertical mark indicating how much of the feeling 




The pleasurable effects of the drugs were measured on a 5-point likert scale from “no” 
to “extreme” on the item “This experience is pleasurable”. This was measured at 
baseline, post-capsule, and post-THC. After the completion of the 2nd experimental 
session, the participants were asked to name which one of the two THC-occasions they 
felt were the weakest or least intense.   
Statistical analyses 
All analyses were performed in SPSS 21 (IBM, N.Y.). Due to the small sample size of this 
study none of the data was normally distributed. Friedman’s non-parametric repeated 
measures ANOVA was used to analyse differences between treatment weeks (1.∆9-
THCV 2.Placebo) across the testing points (1.Baseline, 2.Post-Capsule, 3.Post-∆9-THC). 
Wilcoxon signed-rank test was used for post hoc analyses. Significance was accepted at 
p <0.05, and all comparisons were two-tailed. 
Results 
At the end of the study six out of ten participants correctly guessed which week they 
had been given the ∆9-THCV capsules (χ2=0.4, p=0.527). Table 4.2 lists effects reported 
by study participants while taking either placebo or ∆9-THCV during the study weeks.  






Hopkins Verbal Learning Task 
Immediate recall 
There was no statistically significant change in number of words learned across 
sessions (χ2=4.891, p=0.429). Post hoc analysis did not show any significant differences 
between post-capsule and post-∆9-THC sessions under ∆9-THCV (Z=-1.349, p=0.177) or 
placebo condition (Z=-0.423, p=0.672). 
Delayed recall 
There was a statistically significant decrease in proportion of words recalled across 
sessions (χ2=12.99, p=0.023). Post hoc analysis revealed a significant decrease in words 
recalled between post-capsule and post-∆9-THC session under placebo condition (Z=-
2.201, p=0.028), but not under ∆9-THCV condition (Z=-1.524, p=0.128) There was no 
significant difference between placebo and ∆9-THCV condition at the post-∆9-THC 
session (Z=-1.153, p=0.249) (Figure 4.2 A).  
 
Repetitions 
There was no statistically significant change in repetitions across sessions (χ2=2.755, 
p=0.738). 
Intrusions 
There was a statistically significant increase in intrusions across session (χ2=13.34, 
p=0.02). Post hoc analysis revealed no significant increase between post-capsule and 
post-∆9-THC sessions under placebo condition (Z=-0.954, p=0.34), whereas there was a 
significant increase under ∆9-THCV condition (Z=-2.155, p=0.031). This suggests an 
interactive effect of ∆9-THCV and ∆9-THC to produce a significant increase in intrusions 




Figure 4.2 (A) Proportion of words recalled on the HVLT delayed recall across sessions 















































There was no statistically significant change in numbers recalled across sessions 
(χ2=4.86, p=0.433). Post hoc analysis did not show any significant differences between 
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post-capsule and post-∆9-THC sessions under ∆9-THCV (Z=-1.473, p=0.141) or placebo 
condition (Z=-1.508, p=0.132). 
Digit-span reverse 
There was no statistically significant change in numbers recalled across sessions 
(χ2=8.642, p=0.124). Post hoc analysis revealed a significant improvement in reverse 
digit span performance between baseline and post-capsule and post-∆9-THC sessions 
under ∆9-THCV condition (Z=-2.050, p=0.04) (Figure.4.3). 





















There was no statistically significant change in positive symptom frequency across 
sessions (χ2=8.305, p=0.14). Post hoc analysis revealed a statistically significant 
increase in positive symptoms between post-capsule and post-∆9-THC sessions under 
placebo condition (Z=-2.00, p=0.046), but not under ∆9-THCV condition (Z=-1.342, 
p=0.18). This effect was not significant when comparing baseline and post-∆9-THC 
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sessions under placebo condition (Z=-0.333, p=0.739) (Figure 4.4 A). There was no 
statistically significant change in positive symptom distress scores across sessions 
(χ2=4.00, p=0.549). 
Depressive symptoms 
There was no statistically significant change in depressive symptom frequency across 
sessions (χ2=5.612, p=0.346), or depressive symptom distress score (χ2=5.00, p=0.416). 
Negative symptoms 
There was a statistically significant increase in negative symptom frequency across 
sessions (χ2=22.716, p<0.001). Post hoc analysis revealed significant increases between 
post-capsule and post-∆9-THC sessions under both placebo (Z=-2.328, p=0.02) and ∆9-
THCV conditions (Z=-2.375, p=0.018) (Figure 4.4 B). 
Figure 4.4 (A) Frequency of positive symptoms on the CAPE-state scale (mean ± SEM). 




















































There was a statistically non-significant trend towards a change in hedonic tone scores 
across sessions (χ2=18.619, p=0.068). There were no significant changes between post-
capsule and post-∆9-THC sessions under placebo (Z=0, p=1.00) and ∆9-THCV condition 
(Z=-0.352, p=0.725) (Figure 4.5 A). 
Energetic arousal 
There was a statistically significant decrease in energetic arousal scores across sessions 
(χ2=23.988, p=0.013). Post hoc analysis revealed a significant decrease between post-
capsule and post-∆9-THC sessions under ∆9-THCV condition (Z=-1.99, p=0.047), but not 




There was no statistically significant change in tense arousal scores across sessions 
(χ2=15.248, p=0.171). Post hoc analysis revealed a significant increase between Day 4 
and post-capsule under ∆9-THCV condition (Z=-2.055, p=0.04), but not under placebo 
condition (Z=-1.166, p=0.244) (Figure 4.5 C). 
Figure 4.5 (A) Scores on the hedonic tone subsection of the UMACL across sessions 
(mean ± SEM). (B) Scores on the energetic arousal subsection of the UMACL across 
sessions (mean ± SEM). (C) Scores on the tense arousal subsection of the UMACL 



























































Beck’s Anxiety Inventory 
There was a statistically significant increase in anxiety scores across sessions 
(χ2=31.097, p<0.001). Post hoc analysis revealed a significant increase of anxiety 
between post-capsule and post-∆9-THC sessions under placebo condition (Z=-2.67, 
p=0.008), while this was at a trend level under ∆9-THCV condition (Z=-1.602, p=0.109). 
There were no significant differences of anxiety scores between placebo and ∆9-THCV 
conditions at the post-∆9-THC session (Z=-0.543, p=0.587).  There was no significant 
increase of anxiety between baseline and post-capsule under ∆9-THCV condition (Z=-
1.289, p=0.197) (Figure. 4.6). 























Visual analog scale 
Anxious 
There was no statistically significant increase in VAS anxiety scores across sessions 
(χ2=4.792, p=0.442). Post hoc analysis revealed a non-significant increase in anxiety 
between baseline and post-capsule sessions under ∆9-THCV condition (Z=-1.521, 
p=0.128) (Figure 4.7 A).  
Calm 
There was no statistically significant increase in VAS calm scores across sessions 
(χ2=3.481, p=0.626). 
Tired 
There was a non-significant trend towards increased VAS tired scores across sessions 
(χ2=9.568, p=0.088). Post hoc analysis revealed a non-significant trend towards 
increased tired scores between post-capsule and post-∆9-THC session under ∆9-THCV 
condition (Z=-1.682, p=0.093), but not under placebo condition (Z=-1.362, p=0.173). 
High 
There was a statistically significant increase in VAS high scores across sessions 
(χ2=20.26, p=0.001). Post hoc analysis did not show any significant difference between 
placebo and ∆9-THCV conditions at the post-∆9-THC session (Z=-0.153, p=0.878) 
(Figure 4.7 B). 
Stoned 
There was a statistically significant increase in VAS stoned scores across sessions 
(χ2=33.626, p<0.001). Post hoc analysis did not show any significant difference 
between placebo and ∆9-THCV conditions at the post-∆9-THC session (Z=-0.051, 




Figure 4.7 (A) Scores on visual analog scale for “anxious” (mean ± SEM). (B) Scores on 
visual analog scale for “high” (mean ± SEM). (C) Scores on visual analog scale for 




















































There were no significant changes across sessions in systolic (χ2=20.938, p=0.139) or 
diastolic (χ2=14.444, p=0.492) blood pressure. There was a significant change in heart 
rate across sessions (χ2=27.019, p=0.029). Post-hoc analysis revealed a significant 
increase in heart rate at the ∆9-THC+15min testing point under placebo condition 
compared to ∆9-THCV condition (Z=--2.193, p=0.028) (Figure 4.8). 

























The plasma concentrations of ∆9-THC, 11-OH-∆9-THC under placebo and ∆9-THCV 
condition, as well as ∆9-THCV and 11-OH-∆9-THCV are presented in Figure 4.9 A. There 
were no significant differences between placebo and ∆9-THCV conditions in ∆9-THC 
concentrations at 5 min post-∆9-THC (Z=-1.355, p=0.176) and 1 hour post-∆9-THC (Z=-
1.051, p=0.293). There was a trend towards higher ∆9-THC plasma concentrations 
under placebo condition at the 15 min post-∆9-THC session (Z=-1.718, p=0.086). 
Plasma ∆9-THCV was only above limit of quantification (ALQ, >0.25 ng/mL) in 3 out of 
37 samples, while its main metabolite 11-OH-∆9-THCV was detectable in 11 out of 37 





Figure 4.9 (A) Plasma cannabinoid concentrations of ∆9-THC and 11-OH-∆9-THC under 
placebo and ∆9-THCV conditions (mean ± SEM). (B) Plasma cannabinoid 








































 Subjective effects 
Pleasure 
There was a statistically significant increase in pleasure scores across sessions 
(χ2=16.033, p=0.007). Post hoc analysis did not show any significant difference 
between placebo and ∆9-THCV conditions at the post-∆9-THC session (Z=-0.172, 
p=0.863) (figure 4.10 A). 
∆9-THC strength 
Nine out of ten participants reported ∆9-THC as being either weaker or less intense 




Figure.9 (A) Subjective rating of pleasure across sessions (mean ± SEM). (B) Subjective 
report of the weaker ∆9-THC experience.












































To our knowledge this is the first study exploring the interactive effects of ∆9-THCV 
and ∆9-THC in healthy volunteers. ∆9-THCV was well tolerated among the participants 
and no serious adverse effects were observed. In fact, participants could not 
significantly distinguish the ∆9-THCV capsules from the placebo capsules. However, 
during the ∆9-THCV week, three participants reported feeling more tired than usual, 
while this only occurred for one participant during placebo treatment.  
Cognition 
Interestingly the low dose of 1mg IV ∆9-THC did not produce any significant memory 
impairment on either the HVLT immediate recall or Digit Span task. These results 
highlight the previously shown dose-dependent effects of ∆9-THC (Naef et al., 2004), 
e.g. where higher doses of ∆9-THC have been found to cause anxiety (D’Souza et al., 
2004) while lower doses reduce it (Phan et al., 2008). It has been proposed that this 
may either be due to ∆9-THC acting as a CB1 antagonist at higher doses (Pertwee, 
2008) or disruption of endocannabinoid mediated neuronal firing (Morrison et al., 
2011). There was however a significant drop in performance on HVLT delayed recall, an 
effect that was only present during placebo treatment following ∆9-THC. This drop in 
performance has been well documented in other studies with ∆9-THC, and represents 
impairment in consolidation and retrieval of episodic information from long term 
memory (D’Souza et al., 2005; Morgan, Schafer, et al., 2010). However, previous 
studies have shown ∆9-THC-induced short-term memory impairments to immediate 
recall as well as impairments to consolidation and retrieval, while in this study only 
consolidation and retrieval were negatively affected. This may suggest that 
consolidation and retrieval of episodic memory are more vulnerable to the effects of 
∆9-THC than short-term memory. In previous ∆9-THC studies, CBD has been shown to 
protect against impairments to episodic delayed recall (Englund et al., 2013; Morgan, 
Schafer, et al., 2010). Although ∆9-THC did produce impairments to delayed recall, this 
effect was only present under placebo treatment and absent in the presence of ∆9-
THCV. This suggests a similar protective and antagonistic effect of ∆9-THCV on ∆9-THC 
induced memory impairment. 
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A surprising result was that of a small but significant improvement in performance on 
the Reverse Digit Span task, where ∆9-THCV improved performance compared to 
baseline; while this effect was absent during placebo condition. It is especially 
surprising since no improvements were observed in either the Forward Digit Span task 
or during immediate recall of the HVLT. Since the Reverse Digit Span task requires 
participants to recall the reverse order of a list of digits, it puts a higher demand on 
working memory capacity. Not only do the participants need to hold the information in 
short-term memory, but they also need to manipulate the digits to give the correct 
order. Previous animal studies have shown improvements to working memory 
following either administration of CB1 antagonists (Terranova et al., 1996; Lichtman, 
2000), or genetic deletion of the CB1 receptor (Reibaud et al., 1999). However, there 
are also contradictory findings in the literature where administration of CB1 
antagonists such as Rimonabant have either had no effect on cognition (Hampson and 
Deadwyler, 2000) or an impairing effect (Mallet and Beninger, 1998). Varvel and 
colleagues have argued that this disparity in the literature may be explained by the 
differences in tasks employed, suggesting that CB1 antagonists may facilitate retention 
for longer while having no effect on short term retention (Varvel et al., 2009). This is 
contrary to our findings as I found only a significant improvement on the Reverse Digit 
Span task which requires a response from the participant immediately. Furthermore, I 
observed no improvement in long-term memory as measured by the delayed recall of 
the HVLT. 
Interestingly, I observed a significant interaction between ∆9-THC and ∆9-THCV, which 
produced an increase in intrusions. This effect was not observed under any of the 
other conditions. Intrusions are errors in memory thought to reflect a lack of inhibition 
of semantically related information (Schacter et al., 1998). A study in amnesic patients 
found that intrusions were correlated with verbal fluency (Schnider et al., 1996) which 
is commonly a measure for creativity. Previous studies with high dose IV ∆9-THC have 
reported no significant change in verbal fluency in healthy volunteers (D’Souza et al., 
2004; Morrison et al., 2009), while reporting an increase in intrusions. However, these 
studies all reported impairments to immediate and delayed recall performance, while 
in the current study participants were not impaired following IV ∆9-THC. In a 
naturalistic study, where participants smoked their own cannabis at home, there was a 
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significant increase in verbal fluency after smoking amongst participants low in 
creativity (Schafer et al., 2012). The low dose used in the current study is more likely to 
reflect that of the naturalistic study. Hence, it could be argued that the increase in 
intrusions following the combination of ∆9-THC and ∆9-THCV reflects a similar increase 
in creativity and lacking inhibition, considering the fact that performance was not 
impaired in any of the tested domains. Of course, this remains speculative since verbal 
fluency was not tested in this study. 
Psychological effects 
Similarly to the effects on cognition, the dose of 1mg IV ∆9-THC did not produce any 
significant positive psychotic symptoms or paranoia as has been previously reported 
with higher doses of ∆9-THC (D’Souza et al., 2004; D’Souza, Ranganathan, et al., 2008; 
Morrison et al., 2009, 2011; Englund et al., 2013). In a recent review, I argued that 
previous studies with IV ∆9-THC have administered doses which more reflected an 
over-intoxication of cannabis rather than reflecting recreational cannabis use (Englund 
et al., 2012). The results of the current study are in agreement with this hypothesis. 
There was a significant increase of negative symptoms on the CAPE scale, regardless of 
∆9-THCV or placebo condition, following ∆9-THC; something which has been 
demonstrated with higher doses of ∆9-THC (Morrison and Stone, 2011). The most 
endorsed items were “Do you feel that you are not very animated” and “Do you feel 
that you are lacking in energy”. These results are in line with the post ∆9-THC 
reduction in UMACL Energetic arousal scores in both conditions, and is something that 
has been observed in other ∆9-THC studies (Morrison et al., 2009). 
An interesting trend which emerged was that of apparent increased anxiety at the post 
capsule testing point, only under ∆9-THCV condition. This trend was observed in the 
Beck’s anxiety inventory, VAS anxiety, and UMACL tense arousal. Although there was 
no significant increase across sessions on VAS anxiety, there was a trend towards an 
increase from baseline to post capsule testing points under ∆9-THCV condition. 
Similarly on the UMACL Tense arousal, there was no increase of anxiety across session 
with the exception of a significant increase between day 4 and post capsule testing 
points under ∆9-THCV condition. On the Beck’s scale, there was a significant increase 
of anxiety across session, most likely due to more items relating to the physiological 
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symptoms of anxiety. Similarly, there was a slight increase in anxiety from ∆9-THCV 
between baseline and post-capsule testing points, although this relationship was very 
weak. Seen together, these results seem to indicate a potential, yet weak, anxiogenic 
effect of ∆9-THCV alone. However, it is important to remember that these observed 
small increases in anxiety occurred at the post-capsule testing point which is on the 
same day as IV ∆9-THC administration, where the anticipation of this might provoke 
anxiety. This is highlighted in the UMACL Tense arousal, where there was an increase 
at post-capsule testing point compared to Day 3 and 4. Although, as this effect is 
absent under placebo condition, ∆9-THCV may make participants more sensitive to 
anxiogenic events or stimuli. It is important to note that previous research into the 
effects of CB1 antagonists in healthy volunteers have observed no change to subjective 
mood while showing a significant bias towards negatively loaded words (Horder et al., 
2009, 2012). Future research into the potential anxiogenic potential of ∆9-THCV would 
benefit from employing such tasks to better observe such subtle changes in mood.  
 Subjective effects 
Following completion of both ∆9-THC sessions, participants were asked which ∆9-THC 
session they felt was the weakest or least intense. Nine out of ten reported the ∆9-THC 
session under ∆9-THCV condition to be the weaker/less intense experience, suggesting 
∆9-THCV has a significant impact on the subjective intensity of IV ∆9-THC. 
Furthermore, I asked participants to rate on a 4 point scale how pleasurable they 
perceived the experience. ∆9-THC significantly increased how pleasurable the 
experience was with no difference between placebo and ∆9-THCV condition, 
suggesting that ∆9-THCV does not impact on the pleasurable effects of ∆9-THC. 
Cardiovascular and Pharmacokinetics 
The most common cardiovascular effects of ∆9-THC in humans are tachycardia, 
vasodilatation, increased cardiac output and variable changes to blood pressure 
(Dewey, 1986). In the present study I observed a high variation in both systolic and 
diastolic blood pressure following IV ∆9-THC.  Some participants became momentarily 
hypertensive, while others became hypotensive. This observation sheds some doubt 
on some small but significant differences found in both systolic and diastolic blood 
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pressure. Tachycardia is a more robust effect observed in this study following ∆9-THC 
administration. Interestingly, this effect was blocked by ∆9-THCV suggesting a 
pharmacological inhibition of the peripheral heart rate effects of ∆9-THC. 
The main pharmacokinetic finding in this study was that ∆9-THCV did not significantly 
change plasma levels of ∆9-THC, suggesting that ∆9-THCV does not affect the 
bioavailability of ∆9-THC while still producing measureable changes to its effects. 
Strangely, only 3 out of 37 plasma samples showed levels above quantification. This 
might be due to particularly rapid redistribution of ∆9-THCV, or potentially due to the 
timing of capsule administration. Future studies would benefit from taking these 
factors into consideration and perform more frequent plasma sampling following ∆9-
THCV administration to elucidate its pharmacokinetics. I did however observe 
significantly more samples showing quantifiable levels of the ∆9-THCV metabolite 11-
OH-∆9-THCV (11 out of 37 samples), indicating the recent presence of ∆9-THCV.  
Pharmacological mechanisms 
The pharmacological actions of ∆9-THC have been well established and are mainly 
comprised of partial-agonism at the CB1 receptor. As mentioned previously, other 
pharmacological actions of ∆9-THC are also likely (Pertwee, 2008), although the extent 
to which they influence behavioural effects remain unclear. 
I have previously noted that ∆9-THCV acts as a neutral antagonist in the lower dose-
range (Wargent et al., 2013) while acting as a weak agonist at higher doses (Hollister, 
1974). The current study supports the notion of ∆9-THCV as a competitive antagonist, 
as impairments to delayed verbal recall and heart rate increase were successfully 
inhibited by ∆9-THCV. However, the interaction of both ∆9-THC and ∆9-THCV to 
significantly increase memory intrusions indicate a possible potentiating effect of ∆9-
THCV on specific domains of cognition.  
Strengths and Limitations 
As the present study was a pilot study comprised of only 10 volunteers, this 
significantly impacts on the conclusions that may be drawn from this study. Due to the 
high variation in response to cannabinoids (Atakan, 2012; Englund et al., 2013; 
Morrison and Stone, 2011; D’Souza, Ranganathan, et al., 2008), it is likely that this 
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study was underpowered to capture the variation in responses to ∆9-THCV, with and 
without the presence for ∆9-THC. Furthermore, the decision of timing and dosage of 
∆9-THCV were based on limited information as pharmacokinetic data of ∆9-THCV in 
humans is lacking. This may explain why so few plasma samples showed levels above 
quantification, although rapid redistribution of ∆9-THCV still remains a possible 
explanation. Lastly, the aim of this study was to explore the potential protective effects 
of ∆9-THCV on ∆9-THC-induced psychotic and paranoid symptoms. This was prevented 
as the lower dose of 1mg IV ∆9-THC did not produce significant symptoms. Future 
studies should explore the effects of ∆9-THCV using a higher dose of ∆9-THC. 
Controlled laboratory experiments using pure and isolated cannabinoids benefit from 
reducing inter-individual variation to explore specific psychopharmacological 
interactions. Intravenous administration of ∆9-THC further reduces differences in 
bioavailability between subjects as oral and inhaled administration suffers from poor 
bioavailability and high inter-individual variation (Grotenhermen, 2003). Furthermore, 
the within subject design of the study particularly benefits cannabinoid studies as it 
reduces variation between subjects, which otherwise would require a larger sample 
size. Although this study only recruited participants who had used cannabis 25 times or 
less to minimise variation between subjects, future studies would benefit from also 
recruiting frequent users as they respond differently to cannabinoids (D’Souza, 
Ranganathan, et al., 2008). 
Conclusion 
In this small pilot study with healthy infrequent cannabis users, results indicate that 
the dose of 10mg oral ∆9-THCV is well tolerated with no serious adverse reactions and 
is subjectively not distinguishable from placebo. Furthermore, the lower dose of 1mg 
IV ∆9-THC did not produce any significant short-term memory impairment, as well as 
psychotic or paranoid reactions. ∆9-THCV significantly inhibited ∆9-THC-induced 
impairment to delayed recall as well as ∆9-THC-induced increase of heart rate. ∆9-
THCV on its own showed signs towards improved performance on the harder working-
memory task while also producing a slight increase in anxiety. However, these effects 




Summary and Discussion 
Summary of findings 
In the first experiment, I demonstrated that CBD significantly inhibited ∆9-THC-induced 
paranoid thoughts and impairments to delayed verbal recall. The number of clinically 
significant psychotic reactions induced by ∆9-THC, as measured by the PANSS, was 
significantly reduced by CBD. Furthermore, performance on all working memory tasks 
(digit span forward, reverse, and immediate verbal recall) was impaired by ∆9-THC, an 
effect CBD did not protect against. However, processing speed and executive function 
were not affected by ∆9-THC. 
Secondly, I showed that CBD did not have an effect on ∆9-THC-induced reductions to 
theta amplitude and coherence. However, delta amplitude was significantly increased 
following ∆9-THC administration, an effect that was inhibited by co-administration of 
CBD. Furthermore, alpha amplitude increased for each testing point, although the 
combination of ∆9-THC and CBD inhibited further increases of alpha. Lastly, neither 
theta nor alpha coherence was correlated with change in psychotic symptoms on 
either the PANSS or SSPS. 
Finally, in a small pilot study, I found that a lower dose of IV ∆9-THC (1mg) did not 
significantly increase paranoia, positive psychotic symptoms or impair working 
memory in healthy volunteers. Delayed verbal recall was impaired by ∆9-THC, although 
this effect was blocked by pre-treatment with ∆9-THCV. Also, ∆9-THC-induced heart 
rate increase was inhibited by ∆9-THCV. On its own, ∆9-THCV improved performance 
on one of the working memory tasks and increased anxiety scores, although these 
effects were small.  
How results relate to each other 
From the above mentioned results it seems there potentially lays a threshold level of 
∆9-THC between the two IV doses given (1mg and 1.5mg) in the two studies - a 
threshold which when crossed can result in psychotic symptoms and impairments to 
short-term memory. In the first study 1.5 mg IV ∆9-THC produced positive psychotic 
symptoms and impairments to immediate verbal recall and digit span. However, in the 
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second study, with the reduced dose of 1mg IV ∆9-THC, these effects were absent. 
Potentially, this might mean that certain doses of ∆9-THC are cognitively impairing and 
psychotogenic, while others are not. However, the second study was merely a small 
pilot study and a larger study would be needed for these results to be verified. 
In both studies, co-administration of either CBD or ∆9-THCV significantly protected 
against the impairing effects of ∆9-THC on delayed verbal recall. This finding may 
suggest that both CBD and ∆9-THCV share similar pharmacological properties which 
act to inhibit the memory impairing effects of ∆9-THC. This would most probably be 
the ability of these cannabinoids to antagonise other agonists of the CB1 receptor, as 
∆9-THCV is not known to increase endocannabinoid activity. Although it was clear that 
CBD showed significant protective properties against the psychotogenic and 
cognitively impairing effects of ∆9-THC, these were less evident in the EEG data. ∆9-
THC significantly reduced theta coherence and amplitude regardless of pre-treatment 
group. However, CBD did significantly inhibit ∆9-THC-induced increases to delta 
amplitude, which could potentially relate to its protective effects on the behavioural 
data. Furthermore, there were inconsistencies in the findings concerning the working 
memory tasks between the two analyses. The behavioural study showed poorer 
performance after ∆9-THC on immediate verbal recall and digit span, while during EEG 
recording performance on the n-back task was unchanged. This might be explained by 
the differences between the tasks. The n-back task requires the participant to 
remember and refresh three items (3-back), while digit span and immediate verbal 
recall has up to ten. It may be that previous practice on these tasks prevents a drop in 
performance for the n-back tasks, while digit span and verbal recall remain vulnerable. 
Alpha amplitude was increased after each subsequent testing point, most likely due to 
participant fatigue. ∆9-THC further enhanced this effect, while the combination of 
both ∆9-THC and CBD inhibited further alpha increase. Since alpha amplitude is 
thought to be a sign of neural inhibition, it is therefore possible that ∆9-THC does not 
inhibit neural activity when also taken with CBD. However, this effect was not 
observed in the theta band which is commonly associated with better performance on 
memory tasks. Also, only delayed verbal recall was protected by CBD while working 
memory functions were not. 
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An interesting observation in the EEG data was the apparent lack of effect of CBD on 
measures of amplitude and coherence. These results mimic the ones from the 
behavioural data where CBD on its own had no significant effect on psychological and 
cognitive measures. This is in line with the knowledge of CBD as an endocannabinoid 
enhancer, and the endocannabinoid function as an “on demand” system which lays 
dormant if remained unchallenged. 
Both CBD and ∆9-THCV appear to have no psychoactive effects when taken on their 
own and in the doses mentioned above (CBD: 600mg, ∆9-THCV: 10mg/daily). ∆9-THCV 
however did produce a slight increase in anxiety, although this was only seen on the 
5th day of administration, the day of the experiment, which might indicate that ∆9-
THCV increases sensitivity to stressors. However, the slight increase in anxiety by ∆9-
THCV was reduced by IV ∆9-THC administration.   
How my results relate to other research findings 
In this thesis I have replicated the findings of previous IV ∆9-THC studies which found 
that ∆9-THC significantly induces positive psychotic symptoms in healthy volunteers 
(Morrison et al., 2009; D’Souza et al., 2004, 2005; D’Souza, Ranganathan, et al., 2008; 
D’Souza, Braley, et al., 2008; Barkus et al., 2011; Morrison et al., 2011; Stone et al., 
2012). The rate of participants experiencing psychotic reactions from ∆9-THC in these 
studies ranged from 40-50%. In the first study of this thesis, the rate was 42%, which is 
in line with previous work and strengthens the notion of the psychotogenic effects of 
∆9-THC. It also supports individual resilience towards ∆9-THC in roughly 50% of the 
healthy population. Interestingly, in the second study of this thesis, the lower dose of 
1mg IV ∆9-THC did not produce significant positive psychotic symptoms or paranoia. 
Previous studies have demonstrated that lower doses of inhaled ∆9-THC did not 
produce anxiety or psychosis (Phan et al., 2008; Naef et al., 2004; Brenneisen et al., 
2010), but this is the first study to measure psychotic symptoms at the IV dose of 1mg.   
I have also replicated the finding that CBD counteracts the psychotogenic effects of ∆9-
THC (Di Forti et al., 2009; Morgan and Curran, 2008; Schubart et al., 2011; Leweke et 
al., 2000), and highlighted the specific anti-paranoia effects of CBD. In a clinical trial of 
CBD as an anti-psychotic medication for schizophrenia, Leweke and colleagues 
demonstrated that CBD significantly increased levels of anandamide (AEA) (Leweke et 
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al., 2012). Furthermore, they found that the levels of serum AEA were negatively 
correlated with positive psychotic symptoms. This is in line with their previous 
research where they showed that schizophrenic patients with higher CSF (cerebro 
spinal fluid) AEA had fewer positive psychotic symptoms (Giuffrida et al., 2004) and 
prodromal patients with higher levels transition later into psychotic illness (Koethe et 
al., 2009). In a recent study of CSF AEA levels of healthy cannabis users, the authors 
reported significantly lower levels of AEA in heavy users compared to light users. They 
also reported that levels of AEA were negatively correlated with psychotic symptoms 
while not under the influence of cannabis (Morgan et al., 2013), again highlighting the 
anti-psychotic  effects of increased endocannabinoid signalling. Together, these studies 
suggest it is the increased levels of AEA that are responsible for the anti-psychotic 
effects of CBD in this thesis. However, CBD is also known to strongly antagonise other 
CB1 agonists via an indirect mechanism (Thomas et al., 2007; Pertwee et al., 2002), 
hence it is very likely that both these mechanisms work in concert to protect against 
the psychotogenic effects of ∆9-THC. As mentioned previously, CBD has many more 
pharmacological targets which may also contribute to its effects.These include 
activation of GPR55 (Ryberg et al., 2007), inhibition of adenosine uptake (Carrier et al., 
2006), inhibition of VDAC1 (Rimmerman et al., 2013), transient receptor potential ion 
cannel and 5-HT1A agonism(McPartland et al., 2014), among others. However, further 
studies are needed to elucidate the role of these targets in relation to CBDs anti-
psychotic effects. 
The most consistently reported negative effects of cannabis intoxication are 
impairments to cognitive processes. Previous intravenous studies have reported 
impairments to immediate and delayed verbal recall, executive function and working 
memory, while not affecting verbal fluency and learning (D’Souza et al., 2004; 
Morrison et al., 2009). These studies administered relatively high doses, 2.5mg and 
5mg of IV ∆9-THC to healthy volunteers, while the doses given in this thesis were 
1.5mg and 1mg. The dose of 1.5mg ∆9-THC impaired working memory, immediate and 
delayed verbal recall, while not affecting executive function and speed of processing. 
Relatively, 1mg ∆9-THC impaired delayed verbal recall, while not affecting immediate 
recall or working memory. Taken together, these results suggest that delayed verbal 
recall is the most susceptible cognitive domain as this was still negatively impacted by 
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the lowest IV dose of ∆9-THC given. This was followed in order by: working memory 
(digit span, first reverse then forward), immediate verbal recall, executive function, 
and not significantly affecting learning, speed of processing or verbal fluency. Other 
studies have also reported executive functioning being less impaired by cannabis (Pope 
et al., 1995; Ramaekers et al., 2006b), whist one study found that cannabis improved 
verbal fluency among participants classified as low-creative (Schafer et al., 2012). 
In this thesis, I have shown that both CBD and ∆9-THCV protected the most vulnerable 
of cognitive domains, delayed recall, against the effects of ∆9-THC. Interestingly, CBD 
was unable to protect against the impairing effects of ∆9-THC on digit span or 
immediate recall, while both these domains were unaffected by a lower dose of ∆9-
THC. This suggests that the protective effects of CBD are highly specific, and that CBD 
might not be able to protect against ∆9-THCs effects on working memory if the dose is 
too high. In a naturalistic study where participants smoked their own cannabis, 
Morgan and colleagues found that participants who smoked cannabis with higher 
levels of CBD did not show any impairment to both immediate and delayed recall whist 
intoxicated (Morgan, Schafer, et al., 2010). However, in that study the participants 
were asked to smoke as they normally would to reach their desired level of 
intoxication, while in the studies for this thesis the ∆9-THC doses were fixed. 
The EEG findings of this thesis are somewhat mixed compared to previous research on 
the effects of cannabis or ∆9-THC on electrophysiological measures. Most studies to 
date have reported reductions to theta, alpha and beta power following administration 
of ∆9-THC (Ilan et al., 2004, 2005; Koen B E Böcker et al., 2010). In these studies 
reduction to EEG power were related to impairments to cognitive performance. 
Morrison and colleagues administered 1.25mg IV ∆9-THC to healthy volunteers and 
observed a significant reduction in theta power and coherence (Morrison et al., 2011). 
Alpha power was reduced at trend-level, while the other frequency bands did not 
significantly change. They found that the reduction in bi-frontal theta coherence was 
significantly correlated with positive psychotic symptoms. In the current study, I 
replicated these results in that theta amplitude and coherence were significantly 
reduced following ∆9-THC, although the reduction in theta coherence was not 
correlated with psychotic symptoms. Furthermore, unlike previous studies beta and 
delta amplitude increased following ∆9-THC, and alpha amplitude increased after each 
132 
 
subsequent testing session. Interestingly, CBD significantly inhibited ∆9-THC-induced 
delta increase. However, as ∆9-THC-induced delta increase was not hypothesised a 
priori, correlations between this and psychotic symptoms were not performed. A 
potential explanation for the discrepant findings of this study is that all three recording 
sessions took place on the same day, while previous studies studied participants on 
separate occasions (Koen B E Böcker et al., 2010; Ilan et al., 2004, 2005; Morrison et 
al., 2011). Due to the long experimental day, which included multiple sessions of 
cognitive testing, participant fatigue might have interacted with the pharmaceuticals 
given to produce the results reported here. 
Implications 
This research has potential importance to public health as well as for mental illness. As 
previously discussed, cannabis products are becoming more potent, with growers 
specifically breeding plants high in ∆9-THC at the expense of reduced CBD content. 
People who chose to smoke cannabis today will mostly be exposed to stronger 
cannabis products which may be more harmful to their mental health (Di Forti et al., 
2009), cognition (Morgan, Schafer, et al., 2010), and hold a greater risk of addiction 
(Morgan, Freeman, et al., 2010). Heavy cannabis users, who are more tolerant towards 
the effects of cannabis and require higher amounts of ∆9-THC compared to infrequent 
users (Hirvonen et al., 2012; D’Souza, Ranganathan, et al., 2008), will be at even 
greater risk to the negative effects of cannabis.  
Another source of harm which has recently emerged are in the form of synthetic 
cannabinoid agonists, known commonly as “Spice” (Spaderna et al., 2013). These 
products have recently become increasingly popular as many of them are still not 
illegal and are not detectable by standard urine drug screens. However, many of these 
cannabinoids are far more potent than ∆9-THC and produce a higher prevalence of 
adverse effects (Winstock and Barratt, 2013). A recent report found that admission to 
emergency services was 30 times more likely for people using spice compared to 
regular cannabis (Winstock, 2013). 
The risk of cannabis use to recreational users could potentially be reduced by the 
concomitant use of other cannabinoids such as CBD and ∆9-THCV. This might be 
achieved by either promoting the production of CBD and ∆9-THCV high strains of 
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cannabis, or alternatively prescribing these cannabinoids to frequent users. 
Furthermore, if cannabis use is causally related to the development of psychotic illness 
such as schizophrenia, the presence of CBD may prevent certain individuals from 
developing the disorder.  
Cannabinoids such as CBD may also hold therapeutic potential in treating psychotic 
disorders. So far, naturalistic, observational and experimental studies have repeatedly 
demonstrated the ameliorating effects of CBD against the psychotogenic effects of ∆9-
THC in healthy volunteers. To date, only one clinical trial has shown the efficacy of CBD 
in treating schizophrenia (Leweke et al., 2012). If more studies confirm these findings, 
patients could benefit from an effective anti-psychotic medication with very few and 
mild side effects (sedation at higher doses). Furthermore, it may also benefit some 
patients who have not responded to regular anti-psychotic treatment, as CBD exerts its 
effects via a different pharmacological pathway than the classic dopaminergic one. 
Lastly, cannabinoid receptor antagonists such as ∆9-THCV may show therapeutic 
benefits for various metabolic conditions. The CB1 inverse agonist Rimonabant showed 
great efficacy in decreasing weight and improving cholesterol levels in obese patients 
(Christensen et al., 2007), although it was withdrawn from the market due to 
psychiatric side-effects. Therefore, a CB1 antagonist which does not induce inverse 
agonism, such as ∆9-THCV, could potentially be effective in treating these metabolic 
measures while having a less negative side-effect profile. 
Future directions 
As demonstrated in this thesis, lower doses of ∆9-THC may not induce cognitive 
impairment and psychotic symptoms. Future studies would benefit from employing a 
within-subject design (to eliminate inter-individual variability) to explore a potential 
threshold dose of ∆9-THC which does not produce these negative effects. 
Furthermore, these studies could administer varying doses of both CBD and ∆9-THC to 
potentially find an optimal ratio between the two cannabinoids. Also, the combination 
of both CBD and ∆9-THCV could have a synergistic beneficial effect against the effects 
of ∆9-THC, compared to either cannabinoid administered individually.  
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In this thesis the results of the EEG analyses were somewhat contrary to previous 
studies. Further studies are needed to replicate these findings, preferably testing 
participants on separate days. Also, studying the EEG effects of a wider dose range of 
IV ∆9-THC might elucidate at which dose ∆9-THC begins to disrupt neural networks. 
Similarly, co-administration of different CBD and ∆9-THCV doses would also add to the 
understanding of how these cannabinoids protect neural networks against ∆9-THC. 
Lastly, future studies should further explore the anti-psychotic effects of CBD. These 
studies should aim to treat patients suffering from different forms of psychotic illness, 
preferably with CBD as their sole treatment versus regular anti-psychotic medication. 
Alternatively, studies could explore the benefits of CBD as an addition to regular anti-
psychotic medication, for either first episode patients or those who have been 
resistant to other treatments.  
Publications pending 
The 3rd and 4th chapters of this thesis are currently in preparation and will soon be 














P1 Delusions 1 2 3 4 5 6 7 
P2 Conceptual Disorganisation 1 2 3 4 5 6 7 
P3 Hallucinatory Behaviour 1 2 3 4 5 6 7 
P4 Excitement 1 2 3 4 5 6 7 
P5 Grandiosity 1 2 3 4 5 6 7 
P6 Suspiciousness/persecution 1 2 3 4 5 6 7 
P7 Hostility 1 2 3 4 5 6 7 
N1 Blunted Affect 1 2 3 4 5 6 7 
N2 Emotional Withdrawal 1 2 3 4 5 6 7 
N3 Poor Rapport 1 2 3 4 5 6 7 
N4 Passive/apathetic social withdrawal 1 2 3 4 5 6 7 
N5 Difficulty in abstract thinking 1 2 3 4 5 6 7 
N6 Lack of spontaneity & flow of conversation 1 2 3 4 5 6 7 
N7 Stereotyped Thinking 1 2 3 4 5 6 7 
G1 Somatic Concern 1 2 3 4 5 6 7 
G2 Anxiety 1 2 3 4 5 6 7 
G3 Guilty Feelings 1 2 3 4 5 6 7 
G4 Tension 1 2 3 4 5 6 7 





G6 Depression 1 2 3 4 5 6 7 
G7 Motor Retardation 1 2 3 4 5 6 7 
G8 Uncooperativeness 1 2 3 4 5 6 7 
G9 Unusual Thought Content 1 2 3 4 5 6 7 
G10 Disorientation 1 2 3 4 5 6 7 
G11 Poor Attention 1 2 3 4 5 6 7 
G12 Lack of judgement and insight 1 2 3 4 5 6 7 
G13 Disturbance of Volition 1 2 3 4 5 6 7 
G14 Poor impulse control 1 2 3 4 5 6 7 
G15 Pre-occupation 1 2 3 4 5 6 7 





We are interested in your views. Please circle how much you agree or disagree with the following statements based 
upon your thoughts in the last 15-20 minutes. 
     
                                                                  Do not        Agree a       Agree          Agree         Totally 
  agree           little       moderately   very much    agree 
 
1.  Someone was hostile towards me  1       2            3    4            5 
 
2. No-one had any particular feelings about me 1       2            3    4            5 
 
3.  Someone had bad intentions towards me 1       2            3    4            5 
 
4. Someone was friendly towards me  1       2            3    4            5 
 
5.  Someone was trying to make me distressed 1       2            3    4            5 
 
6. I felt very safe in their company  1       2            3    4            5 
 
7. Someone stared at me in order to upset me 1       2            3    4            5 
   
8. Everyone was trustworthy   1       2            3    4            5 
 
9. Someone wanted me to feel threatened 1       2            3    4            5 
  
10.  I wasn’t really noticed by anybody   1       2            3    4            5 
 
11. Someone had kind intentions toward me 1       2            3    4            5 
 
12. Someone would have harmed me   1       2            3    4            5 
      in some way if they could 
 




14. Everyone was neutral towards me  1       2            3    4            5 
 
15.  Someone was trying to intimidate me 1       2            3    4            5 
 
16. Everyone was pleasant     1       2            3    4            5 
 
17.  Someone was trying to isolate me  1       2            3    4            5 
 
18.  No-one had any intentions towards me 1       2            3    4            5 
 
19.  Everyone seemed unconcerned by my presence1       2            3    4            5 
 








Does the adjective describe your mood in the last 15-20 minutes? 
. 




Happy 1 2 3 4 
Dissatisfied 1 2 3 4 
Energetic 1 2 3 4 
Relaxed 1 2 3 4 
Alert 1 2 3 4 
Nervous 1 2 3 4 
Passive 1 2 3 4 
Cheerful 1 2 3 4 
Tense 1 2 3 4 
Jittery 1 2 3 4 
Sluggish 1 2 3 4 
Sorry 1 2 3 4 
Composed 1 2 3 4 
Depressed 1 2 3 4 
Restful 1 2 3 4 
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Vigorous 1 2 3 4 
Anxious 1 2 3 4 
Satisfied 1 2 3 4 
Un-enterprising 1 2 3 4 
Sad 1 2 3 4 
Calm 1 2 3 4 
Active 1 2 3 4 
Contented 1 2 3 4 

















Instructions: I am going to say a list of numbers. When I am finished I want 
you to tell me the numbers in the order in which they were given. 
Rules: If successful, move on immediately to the next level. Two attempts 
at each level of difficulty. If wrong x 2 then stop and score. 
Name   Date   Code   
Forward Span 
2-9   
7-1   
3-6-5   
2-4-9   
3-1-7-4  start         
4-6-2-9   
1-8-5-2-4   
8-7-1-9-5   
2-4-7-3-9-1   
1-9-5-7-4-3   
5-6-3-9-2-1-8   
6-4-3-2-8-5-1   
2-7-5-8-6-4-9-3   
9-4-3-7-6-2-5-8   
7-4-5-8-4-7-9-3-1   
3-2-6-5-3-7-8-9-2   
5-4-6-8-2-6-3-2-7-9   






Instructions: Again, I am going to say a list of numbers. This time I want 




2-9   
9-4   
7-8-2  start   
5-8-1   
7-8-6-4   
8-4-1-7   
8-2-5-9-4   
5-8-6-3-9   
9-2-4-8-7-1   
3-7-4-9-1-6   
8-7-5-2-6-3-9   
4-8-1-2-5-9-7   
5-9-4-6-5-3-8-7   
9-4-6-2-8-3-7-5   
6-2-4-6-7-3-8-9-5   
7-3-5-7-5-3-2-8-4   
2-4-1-5-6-3-6-7-4-7   






































0Back   D 
0Back   F 
0Back   U 
0Back   X 
0Back   P 
0Back   X 
0Back   N 
0Back   A 
0Back   M 
0Back   R 
0Back   S 
0Back   X 
0Back   W 
0Back   O 
Instr One back 
1Back   F 
1Back   S 
1Back   R 
1Back   R 
1Back   C 
1Back   W 
1Back   V 
1Back   V 
1Back   D 
1Back   A 
1Back   A 
1Back   E 
1Back   Q 
1Back   T 
Instr Two back 
2Back   D 
2Back   B 
2Back   C 
2Back   R 
2Back   S 
2Back   R 
2Back   J 
2Back   U 
2Back   H 
2Back   Y 
2Back   P 
2Back   Y 
2Back   W 
2Back   B 
Instr Three back 
3Back   T 
3Back   S 
3Back   M 
3Back   I 
3Back   J 
3Back   M 
3Back   P 
3Back   D 
3Back   W 
3Back   D 
3Back   S 
3Back   E 
3Back   C 
3Back   U 
3Back   S 
3Back   C 
Instr Is it 'X' 
0Back   J 
0Back   G 
0Back   D 
0Back   M 
0Back   X 
0Back   V 
0Back   N 
0Back   B 
0Back   X 
0Back   H 
0Back   P 
0Back   F 
0Back   I 
0Back   X 
Instr Three back 
3Back   R 
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3Back   P 
3Back   W 
3Back   E 
3Back   G 
3Back   F 
3Back   E 
3Back   L 
3Back   T 
3Back   R 
3Back   S 
3Back   V 
3Back   F 
3Back   E 
3Back   V 
3Back   W 
Instr Two back 
2Back   G 
2Back   B 
2Back   C 
2Back   W 
2Back   O 
2Back   R 
2Back   J 
2Back   R 
2Back   P 
2Back   M 
2Back   Y 
2Back   M 
2Back   W 
2Back   V 
Instr One back 
1Back   F 
1Back   R 
1Back   S 
1Back   S 
1Back   T 
1Back   W 
1Back   C 
1Back   Z 
1Back   D 
1Back   E 
1Back   E 
1Back   A 
1Back   Q 
1Back   T 
Instr Is it 'X' 
0Back   G 
0Back   N 
0Back   K 
0Back   R 
0Back   D 
0Back   T 
0Back   X 
0Back   B 
0Back   H 
0Back   X 
0Back   A 
0Back   I 
0Back   Q 




CAPE-state (Cannabis)  
The CAPE-state is designed to measure feelings, thoughts and mental experiences. We believe 
that these are much more common than has previously been supposed, and that most people 
have had some such experiences during their lives.  
The next pages are divided into columns A and B. Please use column A to indicate if you are 
experiencing the specific feelings, thoughts or mental experiences at this time. Please answer the 
following questions as honestly as you can. There are no right or wrong answers and there are no 
trick questions.  
 
If you answered ‘yes to the question in column A, please circle the number in column B that 
corresponds most closely to how distressing these feelings, thoughts or experiences are to you.  
After this, go to the next question in column A.  
If you answered no to the question in column A, don’t answer the matching question in column B, 
but go straight to the next question in column A.  
 
 
If yes in column A, go to column B. If no in column A, go straight to the next question in column A.  
Column A  Column B  
Do you have a specific feeling, thought or mental 
experience in the last 10 minutes? 
How distressed are you by this 
experience?  
 
ID-no:  Column B  
 not 
distressing  






1) Do you feel sad?  no yes  0  1  2  3  
2) Do you feel as if people 
seemed to be dropping hints 
about you or saying things with a 
double meaning?  
no yes 0  1  2  3  
3) Do you feel that you are not 
very animated?  
no yes 0  1  2  3  
4) Do you feel that you are not 
much of a talker at the moment? 
no yes  0  1  2  3  
5) Do you feel as if things in 
magazines or newspapers were 
written especially for you?  
no yes  0  1  2  3  
6) Do you feel as if some people 
were not what they seemed to 
be?  
no yes 0  1  2  3  
7) Do you feel as if you are being 
persecuted in some way?  
no  yes 0  1  2  3  
8) Do you feel that you 
experience few or no emotions at 
this time?  
no  yes  0  1  2  3  
9) Do you feel pessimistic about 
everything?  
no yes 0  1  2  3  
10) Do you feel as if there is a 
conspiracy against you?  
no yes  0  1  2  3  
11) Do you feel as if you are 
destined to be someone very 
important?  
no yes  0  1  2  3  
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12) Do you feel as if there is no 
future for you?  
no  yes  0  1  2  3  
13) Do you feel that you are a 
very special or unusual person?  
no  yes  0  1  2  3  
14) Do you feel as if you do not 
want to live anymore?  
no yes  0  1  2  3  
 
ID-no:  








15) Do you think that people can 
communicate telepathically?  
no  yes  0  1  2  3  
16) Do you have no interest in 
being with other people?  
no yes 0  1  2  3  
17) Do you feel as if electrical 
devices such as computers can 
influence the way you are 
thinking?  
no  yes 0  1  2  3  
18) Do you lack motivation to do 
things?  
no  yes 0  1  2  3  
19) Are you crying about 
nothing?  
no  yes  0  1  2  3  
20) Do you feel the power of 
witchcraft, voodoo or the occult?  
no yes  0  1  2  3  
21) Do you feel that you are 
lacking in energy?  
no  yes  0  1  2  3  
22) Do you feel that people are 
looking at you oddly? 
no yes  0  1  2  3  
23) Do you feel that your mind is 
empty?  
no  yes  0  1  2  3  
24) Do you feel as if the thoughts 
in your head are being taken 
away from you?  
no  yes  0  1  2  3  
25) Do you feel that you are 
spending your time doing 
nothing?  
no  yes  0  1  2  3  
26) Do you feel as if the thoughts 
in your head are not your own?  
no  yes 0  1  2  3  
27) Do you feel that your 
feelings are lacking in intensity?  
no  yes  0  1  2  3  
28) Are your thoughts so vivid 
that you are worried other people 
might hear them?  
no  yes 0  1  2  3  
29) Do you feel you are lacking 
in spontaneity?  
no yes  0  1  2  3  
30) Do you hear your own 
thoughts being echoed back to 
you?  
no  yes 0  1  2  3  
Column B  
 














31) Do you feel as if you are 
under the control of some 
force or power other than 
yourself?  
no yes 0  1  2  3  
32) Do you feel that your 
emotions are blunted?  
no  yes  0  1  2  3  
33) Do you hear voices that 
other people could not hear?  
no  yes 0  1  2  3  
34) Do you hear voices talking 
to each other that other people 
could not hear?  
no yes  0  1  2  3  
35) Do you feel that your 
appearance or personal 
hygiene are no longer 
important?  
no  yes 0  1  2  3  
36) Do you feel that you 
cannot get things done?  
no yes  0  1  2  3  
37) Do you feel that few things 
are of interest to you?  
no  yes  0  1  2  3  
38) Do you feel guilty about 
something?  
no  yes 0  1  2  3  
39) Do you feel like a failure?  no yes 0  1  2  3  
40) Do you feel tense?  no  yes  0  1  2  3  
41) Do you feel as if a double 
has taken the place of one of 
the people you are in the room 
with?  
no  yes  0  1  2  3  
42) Do you see objects, people 
or animals that other people 
cannot see?  












Below is a list of common symptoms. Indicate how much you have been bothered by that symptom in 
the last 15-20 minutes. 
. 
 Not At All Mildly but it 
didn’t bother 
me much 




Severely – it 





0 1 2 3 
Feeling hot 0 1 2 3 
Wobbliness in 
legs 
0 1 2 3 
Unable to relax 0 1 2 3 
Fear of worst 
happening 
 
0 1 2 3 
Dizzy or 
lightheaded 
0 1 2 3 
Heart 
pounding/racing 
0 1 2 3 
Unsteady 0 1 2 3 
Terrified or afraid 0 1 2 3 
Nervous 0 1 2 3 
Feeling of 
choking 
0 1 2 3 
Hands trembling 0 1 2 3 
Shaky / unsteady 0 1 2 3 
Fear of losing 
control 
0 1 2 3 




Fear of dying 0 1 2 3 
Scared 0 1 2 3 
Indigestion 0 1 2 3 
Faint / 
lightheaded 
0 1 2 3 
Face flushed 0 1 2 3 




Scoring - Sum each column. Then sum the column totals to achieve a grand score. 
Write that 






Visual Analogue Scale  
 
High: Giggly, full of life, mischievous, playful, seeing the funny side of things, interested in 
others, the situation, percepts and ideas, light, cheerful, word-play, seeing connections, 
jocular, creative.  
       
 
      “Feeling high” 
              0             10 
 
 
     Not high at all     As high as could possibly be 
 
 
Anxious: Feeling fearful and panicky, anticipating something bad to happen with dry mouth, 
muscles tension, hand/knee shakes, sweating, shortness of breath, dizziness, butterflies in 





      “Feeling anxious” 
              0             10    
 
 




Tired: Lacking in energy, feeling drained, wanting to lie down. 
 
 
      “Feeling tired” 
              0             10   
 
 





Calm and relaxed: Feeling at peace, with no muscle tension. 
 
             “Feeling calm and relaxed” 
              0             10    
 
 





Stoned: Slowed up, introverted, reduced capacity for thought, movement and emotion, 
feeling less reactive, sleepy, heavy and dull. Disinterest in others and the surroundings. 
Closed off. 
 
      “Feeling stoned” 
              0             10    
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